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The spectrin superfamily is a group of proteins that have similar structural and 
functional features. They are present in several tissues but have different names. Spectrin 
is present in erythrocytes, dystrophin in muscle tissues, fodrin in brain and other tissues, 
and a-actinin in skeletal, cardiac and smooth muscles (Dhermy, 1991; Winkelman and 
Forget, 1993). It is named the spectrin superfamily since spectrin is the most studied 
member of the family. It is the main component of a two dimensional network of proteins 
called the erythrocyte membrane skeleton, that is underlying the surface of the erythrocyte 
membrane (Marchesi and Steers, 1968; Branton et al., 1981; Gratzer, 1983; Gratzer, 
1984; Bennett, 1990). 
The erythrocyte membrane skeleton interacts with several integral membrane 
proteins thus influencing the lateral mobility of these proteins (Goodman and Branton, 
1978). Beside interacting with the integral proteins, the membrane skeleton interacts with 
lipids in the membrane (Mombers et al., 1980; Maksymiw et al., 1987; Subarrao et al., 
1991). Through all these interactions, the membrane skeleton provides support to the lipid 
bilayer so it can withstand the shear pressure that erythrocytes have to endure passing 
through blood vessels. This support is essential for the survival of erythrocytes (Lux and 
Glader, 1981; Marchesi, 1985; Elgsaeter and Mikkelson, 1991 ). 
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Spectrin was purified for the first time from the erythrocyte membrane skeleton 
in 1968 (Marchesi and Steers, 1968). Purified spectrin was found to constitute 25-30% 
of the total erythrocyte membrane protein (Marchesi et al., 1971; Fairbanks et al., 1971 ; 
Steck, 1974). When the purified spectrin was run on sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE), it appeared on the gel as two bands with 
apparent molecular weight of 260 kD for the first band and 225 kD for the second band. 
Thus the two subunits of spectrin are often referred to as Band 1 and Band 2 (Steck, 
1974), or as a- and P-spectrin. 
Due to the large size and the shape of the spectrin molecule, it is difficult to apply 
nuclear magnetic resonance (NMR) or X-ray crystallography to study its structure. 
However, other techniques have been used to obtain structural and physical properties of 
spectrin. For example, electron microscopy (Shotton et al., 1979) and sedimentation 
velocity (Ralston and Dunbar, 1979), studies of spectrin suggest that spectrin heterodimer 
is a 100 nm long, rod-like molecule with a diameter of 4-6 nm. Additional structural 
information was obtained on negatively stained spectrin in the partially expanded 
membrane skeleton, suggesting that the a- and P-spectrin subunits twist around each 
other forming a two-stranded helix with a pitch of about 104-106 A and a diameter of 
about 36-52 A (McGough and Josephs, 1990). Circular dichroism (CD) (Ralston, 1976) 
and Fourier transform infrared (FTIR) (LaBrake and Fung, 1993) studies suggest that 
spectrin contains 60-75% a-helix. 
Spin labeling electron paramagnetic resonance (EPR) studies showed different 
types of motions (Fung et al., 1979; Cassoly et al., 1980; Dubreuil and Cassoly, 1983; 
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Fung and Johnson, 1983; Streichman et al., 1991; Hensley et al., 1993). The combination 
of conventional and saturation transfer EPR methods was used to determine the motions 
of these spin labels to be in the time ranges of 10-9, 10-1, 10-6 and 10-3 s (Fung et al., 1979; 
Fung and Johnson, 1983). Dynamic light scattering was also used to study the segmental 
motion of spectrin tetramer (Budzynski et al., 1992). It measured fluctuational segmental 
motions over a distance of20-30 nm with relaxation times equal or less than 23 µs. These 
studies show that spectrin is a highly flexible molecule, which is understandable since it 
contributes to the deformability and elasticity properties of human erythrocytes. 
The ex- and P-spectrin subunits interact side-to-side in an antiparallel manner to 
form the spectrin dimer (Speicher et al., 1982). This interaction starts at a nucleation site 
which is at the C-terminal end of the ex-subunit and the N-terminal end of the P-spectrin 
followed by several interaction sites along the length of each of the two subunits (Speicher 
et al., 1992). Two of the spectrin dimers can associate head-to-head (the N-terminal 
region of the ex-subunit in one dimer interacting with the C-terminal region of the P-
subunit on the other dimer) to form the spectrin tetramer (Ungewickell and Gratzer, 1978; 
DeSilva et al., 1992; Speicher et al., 1993), which is the predominant form in erythrocytes 
(Byers and Branton, 1985; Liu et al., 1987). Diseases that are associated with abnormal 
red blood cell shape such as hereditary elliptocytosis and hereditary pyropoikilocytosis 
were found to have deficiency in spectrin tetramer and to be caused by mutations in the 
N-terminal region of the ex-spectrin (Boulanger et al., 1994; Gallagher et al., 1992; 
Lecomte et al., 1989) or in the C-terminal region of the P-spectrin (Gallagher et al., 1995; 
Sahr et al., 1993; Tse et al., 1990) subunits. Most of the mutations in the ex-spectrin 
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subunit were found to be within the first 150-200 amino acid residues. These mutations 
were suggested to destabilize the head-to-head interactions and thus the tetramer 
formation. Binding constants of spectrin dimers to give tetramer at 3 7 C was about 2 x 
105 M-1 (Ungewickell and Gratzer, 1978; DeSilva et al., 1992). 
Recombinant a-spectrin peptides were used to study the domain structure and their 
binding with (3-spectrin, to understand the role of spectrin in maintaining the biconcave 
shape of normal erythrocyte. 
The amino acid sequence of the a- and f3-spectrin subunits showed that both 
subunits contain homologous amino acid sequences of about 106 reisdues long (Sahr et 
al., 1990; Winkelman et al., 1990). The first 150-200 amino acid residues contain such 
homologous sequence. The presence of these homologous sequences suggested the 
presence of structurally stable domains and the structure of a- and P-spectrin subunits to 
be as a string of structural domains. Thus studies of the structure of these homologous 
sequences are essential in solving the structure of the part of molecule containing the first 
150-200 amino acid residues, and of the entire molecule. 
The presence of structural domains within the homologous sequence led to the 
question of where is the start of the domain structure? For example, in the sequence 
ABCDEFABCDEFABCDEF, a domain of 6 letters could start with the letter A and the 
domain would be ABCDEF, at Band the domain would be BCDEFA, or at C and the 
domain would be CDEF AB. Thus six different possibilities appear for a six letter domain, 
and about 106 different possibilities for spectrin domains. Assuming that folded domains 
will be digested slower that the non-folded part, various fragments of spectrin were 
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prepared by recombinant techniques and subjected to digestion by proteases. Protease 
products were separated for N-terminal sequencing to determine the start of the domain. 
The first amino acid residue in the structural domain was determined to be 26 amino acid 
residues downstream from the beginning of the sequence motif for Drosophila a -spectrin 
(Winograd et al., 1991). Assuming that human a-spectrin has the same phase shift as 
Drosophila a-spectrin, the first amino acid residue in the first structural repeat would be 
amino acid residue number 49. Another study suggested that the start of the first 
structural repeat is amino acid residue number 54 (Speicher et al., 1993). However, the 
start of human a-spectrin is not clear. 
Based on the findings that spectrin is highly helical, the length of the spectrin 
subunits of 100 nm is approximately one third the length of an a-helix of 2, 000 amino acid 
residues, the amino and carboxy termini of the subunits are located opposite to each other 
in the spectrin molecule, and spectrin is more flexible in solution than coiled-coil a-helical 
proteins, a triple a-helical bundle was suggested as the structure for the 106 amino acid 
sequence (Speicher and Marchesi, 1984). A modification of the above model showing the 
three helices (A, B and C), with the last helix (C) in the nth repeat and the first helix (A) 
in (n + l)th repeat forming a one long helix (CA) (Parry and Cohen, 1991; Parry et al., 
1992). X-ray crystallography of a folded domain from Drosophila a-spectrin supports 
this model (Yan et al., 1993). 
In this study, various recombinant a-spectrin peptides were used to study the N-
terminal region of a-spectrin that is important in the binding of P-spectrin. 
In the first part of this study, 8 peptides with different lengths were expressed and 
6 
purified. Limited protease digestion combined with amino acid sequencing were used to 
determine the start of the first structural domain of the cx-spectrin subunit. This work, in 
collaboration with other members in our laboratory, was published in 1994 (see 
Appendix). 
In the second part of the study, two different cx-spectrin peptides and P-spectrin 
subunit were prepared for binding studies. Three different techniques--Superose 6 size 
exclusion gel chromatography, combined radiolabeling with western blotting and 
immunoprecipitation of radiolabeled peptides--were used to obtain binding constants. 
These binding constants were shown to be comparable with spectrin dimer-dimer binding 




MATERIALS AND METHODS 
Chemicals and Equipment 
All general chemicals were obtained from Sigma chemical Company (St. Louis, 
MO), Curtin Matheson Scientific, Inc. (Wooddale, IL), or Fisher Scientific (Pittsburgh, 
PA). Specific chemicals such as 4-maleimido-2,2,6,6-tetramethyl-l-piperidinyloxy (Mal6) 
was obtained from Aldrich Chemical Company Inc. (Milwaukee, WI); Ampicillin and 
glutathione Sepharose 4B resin from Pharmacia Biotechnology (Piscataway, NJ); protein 
molecular weight standards from Gibco BRL Life Technologies Inc. (Gaithesburg, MD); 
dye reagent for protein assay from Bio-Rad (Richmond, CA); isopropyl-B-D-
thiogalactoside (IPTG) from Promega Company (Madison, WI); 125I from ICN (Costa 
Mesa, CA). cDNA of spectrin was a generous gift from Dr. B. G. Forget of Yale School 
of Medicine, New Haven, CT. All equipment were available in our laboratory with the 
exception of the gamma counter which is in the Department of Biology. 
2.2 Cloning and Expression of a-Spectrin Peptides 
2.2.1 DNA Preparation 
Sense and antisense oligonucleotide pnmers were synthesized by National 
7 
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Biosciences (Plymouth, MN). The primers were dissolved in deionized water by heating 
to 65 °C for IO minutes to give a final concentration of 100 pmole/ µl. The solution was 
stored in aliquot at -70°C to avoid repeated freezing and thawing. A 200 µl PCR cocktail 
was prepared by adding 2 µl of the sense oligonucleotide, 2 µl of the antisense 
oligonucleotide, 10 µl of 20X buffer (supplied by the company), 4 µl of 10 mM dTNPs, 
179 µl of sterile deionized water, 2 µl of template (cDNA clone a3), and finally 1 µl of 
Taq polymerase in a 1.5 ml microfuge tube. The tube was placed in a thermal cycler 
(Eppendorf Microcycler) and 1 parafilm bead added to the mixture. The PCR was 
programmed to run 35 cycles of30 seconds at the denaturation temperature (95°C), 45 
seconds at the annealing temperature (calculated using the equation Tm = 4 x ( G or C) + 
2 x (A or T), where G,C,A and Tare the number of deoxyguanylate, deoxycytidylate, 
deoxyadenylate and deoxythymidylate in the primers, respectively), and 60 seconds at the 
polymerization temperature (72°C). 10 µl of the resulting mixture was loaded on an 
agarose gel to check if the expected DNA piece was made. A standard of 100 bp was 
loaded on the adjacent well to check if the DNA piece has the correct length. Then the 
Promega magic PCR prep DNA purification system (Promega, Madison, WI) was used 
to purify the DNA piece out of the mixture giving 50 µl of DNA solution. 
2.2.2 DNA Agarose Gel Electrophoresis 
To purify DNA fragments, 1 % agarose gels were prepared. 0.5 g of agarose was 
added to 50 ml of TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM EDT A) and 
dissolved by boiling the solution. The solution was stirred until it cooled down and 
ethidium bromide was added to give a final concentration of0.5 µglml (2.5 µl of 10 mg/ml 
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stock solution). After solution cooled down further, it was poured into a horizontal gel 
cast. After gel hardened at room temperature, the cast was moved to the gel chamber and 
TBE buffer added. DNA samples were prepared by adding a 2X loading buffer containing 
a tracing dye (orange G). Gel samples were loaded onto the gel and electrophoresis ran 
under constant voltage of 50 V until desired separation was reached. The separation was 
followed using a MINERALIGHT LAMP (UVP INC, San Gabriel, CA). 
2.2.3 Spectrin Construct Preparation 
Ten ml of overnight culture of cells containing the pGEX-2T vector were pelleted 
down and the supernatant decanted. The Promega magic PCR prep DNA purification 
(Promega, Madison, WI) system was used to give a 50 µl purified vector solution. 2 µl 
was electrophoresed on an agarose gel to check the presence of the vector. 
The purified DNA pieces and the pGEX-2T vector were digested by incubating 20 
µl of each with 5 µl of buffer 3 (IOX, supplied by the company), 1 µl ofEcoRI, lµl of 
BamHI and deionized water to 50 µl in a water bath at 37°C for 2 hours. The cut DNA 
pieces and vector were purified on an agarose gel by excising the desired bands off the gel 
followed by extraction of the DNA from the excised bands. The gel bands were 
transferred to 0.5 ml microfuge tube containing glass wool and has a hole at the bottom. 
The microfuge tube was placed in a 1. 5 ml microfuge tube and centrifuged at 2, 000 g for 
10 minutes. The 0.5 ml microfuge tube was discarded. The DNA was further purified by 
phenol extraction. O.SX the DNA solution volume of phenol was added and the solution 
was spun for 2 minutes in a picofuge. To the phenol layer (upper layer), O.SX the volume 
of chloroform was added and the tube spun for 2 minutes in a picofuge. To the aqueous 
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layer, o. l X the volume of 3M sodium acetate, 2X the volume of 100% ethanol and 2 µg 
of yeast tRNA (for vector only) were added. The mixture was incubated on dry ice for 15-
20 minutes followed by spinning the tube for 20 minutes at 15, 000 g. After decanting the 
supernatant, the pellet was washed with 200 µl of 70% ethanol and spun for 5 minutes at 
15,000 g. The solution was dried by heating at 65°C for 5 minutes. Ten µl of 10 mM 
Tris, 0.1 mM EDTA, pH 8.0 was added to the tube and heated at 65 °C for 5 minutes. 4 
µl of the final solution was electrophoresed on an agarose gel to check the purity of the 
samples. 
Two µl of the vector and comparable amount of the DNA piece were combined 
in a microfuge tube along with 1 µl ofT4 DNA ligase (Epicenter Technologies, Madison, 
WI), 1. 5 µl of the 10 X buffer (supplied with the ligase ), 1 µl of ATP and deionized water 
to 15 µl. The mixture was incubated at 15 ° C overnight followed by a second incubation 
at 65 °C for 10 minutes to deactivate the ligase. 
A mixture of 100 µl HB 101 competent cells and 5 µl plasmid were mixed and 
incubated on ice for 30 minutes. Then 300 µl of TSS (0.5% sodium chloride, 1% 
tryptone, 0.5% yeast extract, 10% PEG, 5% DMSO, and 50 mM magnesium chloride) 
buffer was added and the mixture was incubated with shaking for 60 minutes. The cells 
were poured and smeared on an agar plate and the agar plates were left overnight at 3 7 ° C. 
Colonies were tested for correct transformation as described below in section 2.3.1. 
Colonies producing fusion proteins were then smeared on agar plates and incubated 
overnight at 37°C. The agar plates were kept for up to 1 month afterwhich the cells were 
smeared on a new agar plate. 
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Cells containing plasmids of all the peptides used in this project were prepared by 
Dr. M.R. Kelley either while he was at Loyola Medical School or while he is at Riley 
Hospital for Children , University oflndiana , Indianapolis, IN. Cells prepared by Dr. M. 
R. Kelley include Spa 1-166(S12C) with the serine residue at position 12 replaced with 
cysteine. 
2.3 Expression, Purification and Digestion of GST-Fusion Proteins 
2.3.1 Testing Cells For The Ability to Express Fusion Proteins 
Cells were inoculated (-4:30 p.m.) into two test tubes each containing 2 ml of 
autoclaved medium (prepared as described in section 2.3.2 below) and Ampicillin added 
to a final concentration of 0 .1 mg/ml. The cells were incubated overnight at 3 7 ° C with 
shaking at 225 rpm. At 9:00 a.m. the following day, 100 µl aliquot of each of the test 
tubes was added to another test tube containing 1. 9 ml of autoclaved medium and 
Ampicillin added to a final concentration of 0.1 mg/ml. At 11 :30 a.m., isopropyl-P-D-
thiogalactoside (IPTG, Pharmacia Biotechnologies, Piscataway, NJ) was added to one of 
the two test tubes to a final concentration of 0.1 mM. At 3 :30 p.m., cells were harvested 
by removing 1. 5 ml from each test tube to a microfuge tube. The microfuge tubes were 
centrifuged for 5 minutes at 15000 xg and the supernatant discarded. 100 µl of 
electrophoresis sample buffer was added to the pellet, mixed, and boiled for 5 minutes. 
The two samples, with and without IPTG, were ran side to side on a gel to determine 
whether fusion protein was induced in sample containing IPTG. 
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2.3 .2 Cell Growth 
Medium was prepared by dissolving IOg/L oftrypton, Sg/L of yeast extract, and 
Sg/L NaCl in water and autoclaved. Cells were inoculated in autoclaved medium (4-S 
p.m.) and Ampicillin added to a final concentration of 0.1 mg/ml. The cells were left to 
grow overnight at 37°C with shaking at 22S rpm. At 9:00 a.m. (O.D. 600 = -2) the cells 
were diluted 1 :20 in autoclaved medium and ampicillin added to a final concentration of 
0.1 mg/ml. The solution was left at 37°C with shaking at 200 rpm for 2.S hours. At 
11:30 a.m. (O.D.(>(J() = O.S-1, the mid-log phase), IPTG was added to a final concentration 
of 0.1 mM. The solution was left at 37°C with shaking at 200 rpm for 4 hours (3 :30 p.m., 
O.D.(>(J() = -2). Cells were harvested by centrifuging the resulting solution at SOOO rpm for 
10 minutes in a Sorvall RC-SB Refrigerated Superspeed Centrifuge (Du Pont Instruments, 
Wilmington, DE) with GSA rotor. Cells, if not used, were stored at -70 ° C until needed. 
2. 3. 3 Fusion Protein Purification 
Cells, if frozen were thawed at 4 °C for l S-30 minutes and S-10 ml of 1 % Triton 
X-100 in PBS were added per gram of cells. They were lysed either by sonication or by 
freeze-thaw followed by sonication. Cell lysate was centrifuged at 10,000 rpm for 10 
minutes in a Sorvall RC-SB centrifuge with SS34 rotor. The supernatant was collected 
and loaded on a glutathione affinity column pre-equilibrated with phosphate buffered saline 
at pH 7.4 (PBS7.4). After incubating the supernatant on the column for 5 minutes, it was 
eluted out of the column by free flow. The column was washed with PBS7.4 buffer until 
the absorbance at 280 nm decreased below 0.020. After that, the column was washed with 
SO mM Tris pH 8.0 buffer containing S mM fresh glutathione. The peak containing the 
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fusion protein was collected and concentrated using Stirred Cells with PMlO Disc 
Membranes (Amicon, Beverly, Mass). 
2.3.4 GST Purification 
Same procedure as above except E. coli cells containing the pGEX-2T vector 
rather than modified vectors were used to get GST rather than GST-spectrin fusion 
protein. 
2.4 Purification of a-Spectrin Peptides 
2.4.1 Thrombin Cleavage of Fusion Proteins 
In order to determine the optimum incubation time that would produce maximum 
digestion and minimum degradation of the spectrin peptide, a time study was performed. 
The concentrated protein was dialyzed against 50 mM Tris, 10 mM EDTA pH 8.65 
buffer. The concentrated and dialyzed protein was loaded onto a thrombin column 
(thrombin covalently linked to agarose beads, CalBiochem, San Diego, CA) with up to 50 
mg of fusion protein per 1 ml of resin and SDS-PAGE samples were taken every several 
hours. 24 hours incubation at room temperature was found to be sufficient. The mixture 
of GST, spectrin peptide and residual fusion protein was eluted out of the column. 
2.4.2 Affinity Purification of a-Spectrin Peptides 
The eluted mixture from the thrombin column was loaded onto a glutathione 
affinity column pre-equilibrated with PBS7.4 buffer. The spectrin peptide was eluted by 
washing the column with PBS7.4 buffer. GST and residual fusion protein were removed 
by washing the column with 50 mM Tris pH 8.0 buffer containing 5 mM fresh glutathione. 
14 
The spectrin peptide solution was concentrated using Stirred Cells and YM3 Disc 
Membranes. 
2.4.3 FPLC Purification 
The FPLC system (Pharmacia Biotechnologies, Piscataway, NJ) contains two P-
500 pumps (A and B), LCC-500 controller, Single Path Monitor UV-1 optical unit, 
FRAC-100 fraction collector, and a chart recorder. Hemoglobin purified by ion-exchange 
chromatography was used as a reference sample to check column performance. A salt 
gradient was created by using two buffers: the first was 10 mM Tris, pH 7.8 with no salt 
while the second was 10 mM Tris, pH 7.8 with 1 M NaCl. Frozen hemoglobin was 
thawed immediately before use. It was diluted to 2 ml and filtered through 0.22 µm filter 
before 100 µl of the filtered sample was loaded onto the FPLC Mono Q column pre-
equilibrated with 10 mM Tris, pH7.8 buffer. 10 ml of the buffer was used to allow all 
neutral and positively charged species to elute out of the column. The salt concentration 
in the buffer was increased to 500 mM (10 mM Tris and 500 mM NaCl), and 35 ml was 
used to elute negatively charged species, 10 ml of the starting buffer was used to re-
equilibrate the column. Flow rate used was 0.5 ml/min. Five peaks were obtained. The 
first two peaks were the major peaks and appeared at the beginning, before the salt was 
passed through the column. The other relatively small three peaks eluted at salt 
concentrations of96 ± 13, 129 ± 9, 154 mMNaCl, respectively (n = 8). 
2.4.3.1 FPLC Purification of GST Protein 
The glutathione affinity purified GST was loaded onto a Mono Q HR.5/5 column 
pre-equilibrated with 10 mM Tris pH 7.8. A salt gradient was created using 10 mM Tris 
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pH 7.8 as buffer 1 and 10 mM Tris, 1 M NaCl, pH 7.8 as buffer 2. Used 10 ml of buffer 
1 (salt concentration at 0 mM) to allow all neutral and positively charged species to elute 
out of the column. Mixed buffer 1 and buffer 2 to give 500 mM salt concentration, and 
maintained for 25 ml to elute the GST protein, increased to 1 M NaCl and stay there for 
5 ml to elute any remaining material off the column. Returned to buffer 1 to re-equilibrate 
the column. The flow rate used throughout the program was 0.50 ml/min. 
2.4.3.2 FPLC Purification of a-Spectrin Peptides 
The glutathione affinity purified spectrin peptide was dialyzed against 40 mM Tris 
pH 7.5 buffer. The dialyzed spectrin peptide was loaded onto a Mono Q HR5/5 or 
HRl0/10 column pre-equilibrated with the 40 mM Tris, pH 7.5 buffer. Two buffers were 
used to create a salt gradient, buffer A, 40 mM Tris pH 7.5 with no salt and buffer B, 40 
mM Tris pH 7.5 containing 500 mMNaCI. All peptides except for Spa 1-49, Spa49-167 
and Spa 1-446 were purified using the following procedure: The salt concentration 
remained at 0 mM for 40 ml to elute all neutral and positively charged species off the 
column. The gradient was increased to 125 mM NaCl after 40 ml and to 155 mM NaCl 
after another 50 ml to elute the spectrin peptides. The salt concentration was increased 
to 500 mM NaCl to clean the column before re-equilibrating it with buffer A The flow 
rate used was 2 ml/min. 
The following procedure was used for Spa 1-49: 10 ml buffer A to elute neutral 
and positively charged species off the column. The gradient was increased to 300 mM 
NaCl after 50 ml to elute Spa 1-49 before increasing it to 1 M to clean the column. The 
column was finally re-equilibrated with starting buffer. The flow rate used throughout the 
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program was 0.50 rnVmin. 
Affinity purified Spa49-167 contained another peptide that elute at the same 
position when the above program was used. Thus a slower gradient was required to purify 
this peptide. The following procedure was used: 40 ml of buffer A to elute all neutral and 
positively charged species off the column. The gradient was increased to 100 mM Na Cl 
after 10 ml and remained at that concentration for 55 ml to elute the contaminating band. 
Spa49-167 eluted by increasing the salt concentration after 20 ml to 125 mM NaCl 
followed by another increase after 50 ml to 155 mM NaCl. The column was cleaned by 
increasing the salt concentration to 500 mM NaCl before re-equilibrating the column with 
buffer A The flow rate used throughout was 2 rnVmin. 
Spa 1-446 was purified using the following procedure: 40 ml buffer A to elute 
neutral and positively charged species. The salt concentration was increased to 13 5 mM 
NaCl and remained constant for 120 ml to elute other contaminants. Spa 1-446 was eluted 
by increasing the salt concentration after 24 ml to 175 mM and keeping it constant for 64 
ml. The column was cleaned by increasing the salt concentration to 500 mM NaCl before 
re-equilibrating the column with the starting buffer. 
2.5 Protein Gel Electrophoresis 
2. 5 .1 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-P AGE) 
The SDS-PAGE was done according to the method of Laemmli (Laemmli, 1970) 
with modifications using the Bio-Rad (Richmond, CA) mini-protein II electrophoresis cell. 
The lower separating gel consisted of380 mM Tris, 0.1% (WN) SDS, 0.033% (WN) 
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ammonium persulfate, 0.067% (VIV) TEMED(Bio-Rad, Richmond, CA), and pH 8.8 with 
the acrylamide varying between 3-16% (WN) and the N,N'-methylene bisacrylamide 
varying between 0.08-0.43% (WN). It was made by adding the appropriate amounts of 
4X buffer (1.52 M Tris, 0.4% (WN) SDS, pH 8.8), 10% (WN) ammonium persulfate, 
30% (WN) acrylamide-0.8% (WN) N,N-methylene bisacrylamide solution, TEMED, and 
autoclaved deionized water. The upper stacking gel consisted of 3. 9% (W N) acrylamide, 
0.1 % (WN) N,N'-methylene bisacrylamide, 125 mM Tris, 0.1 % (WN) SDS, 0.05% 
(WN) ammonium persulfate, 0.1% (VN) TEMED, and pH 6.8. It was made by adding 
the appropriate amounts of 4X buffer (500 mM Tris, 0.4% (WN) SDS, pH 6.8), 10% 
(W/V) ammonium persulfate, 30% (WN) acrylamide-0.8% (WN) N,N'-methylene 
bisacrylamide solution, TEMED, and deionized water. Gel thickness was made 0. 75 mm 
by using 0.75 mm spacers. Gel samples were prepared by adding equal volume of protein 
sample and 2X sample buffer containing 125 mM Tris, 20% glycerol, 4.1% (W/V) SDS, 
2% (V/V) P-mercaptoethanol (PME) and 0.001% Bromophenol Blue, pH 6.8 followed 
by boiling the sample for 5 minutes. Sample size ranged between 1- 25 µl depending on 
the peptide concentration (0.1-10 µg of peptide). Molecular weight standards (the low 
molecular weight standards: ovalbumin (43.0 kD), carbonic anhydrase (29.0 kD), P-
lactoglobulin (18.4 kD), lysozyme (14.3 kD), bovine trypsin inhibitor (6.2 kD) and insulin 
(a and p chain) (2.3 and 3.4 kD, respectively), or the high molecular weight standards: 
myosin (H-chain) (200 kD), phosphorylase B (97.4 kD), bovine serum albumin (68.0 kD), 
ovalbumin (43.0 kD), carbonic anhydrase (29.0 kD), P-lactoglobulin (18.4 kD) and 
lysozyme (14.3 kD) were used. Gels were ran in a buffer consisted of25 mM Tris, 192 
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mM glycine, and 0.1% SDS at a range of 120-160 V. Electrophoresis was stopped 
when the dye front reached -0. 5 cm from the bottom of the gel ( 40-7 5 minutes depending 
on the percentage of acrylamide in the gel-4%-16%). 
2.5.2 Non-Denaturing Polyacrylamide Gel Electrophoresis 
Bio-Rad (Richmond, CA) mini-protein II electrophoresis cell was used to run the 
non-denaturing PAGE. Separating gel, stacking gel, and electrophoresis buffer were the 
same as those for SDS-PAGE but contained no SDS. Sample buffer also contained no 
SDS or PME. Gel thickness was 1.5 mm. All other conditions were the same as those 
for the SDS-PAGE. 
2.5.3 Coomassie Blue Staining 
Both SDS-PAGE and non-denaturing-PAGE were stained in the same way. After 
running the gels, they were immediately transferred to a petri dish containing fixing 
solution ( 40% (V N) methanol, 10% (V N) acetic acid) and left on a rotator for 2 hours 
(-60 rpm). The gels were transferred to another petri dish containing the staining solution 
(0.05% (WN) Coomassie Blue R-250) and left on the rotator for another 2 hours. After 
that the gels were transferred back to the fixing solution for destaining. The destaining 
solution was changed several times until destaining was complete. The number of changes 
and the time of destaining differed depending on the type of gel and the percentage of 
acrylamide. Non-denaturing gels required extensive (- 1 day) destaining. The gels were 
then stored in 5% acetic acid before drying. 
2.5.4 Silver Staining 
Silver staining was done according to published literature (Merril et al., 1983). 
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After running a gel with 10 - 300 µg of samples per well, the gel was placed in fixing 
solution (20% (w/v) trichloroacetic acid) for one hour. The gel was washed twice with 
washing solution (10% ethanol, 5% acetic acid), the first for 10 minutes and the second 
for 20 minutes. The gel was placed in a soaking solution (3 .4 mM potassium dichromate, 
3.2 mM nitric acid) for 5 minutes before staining it in 12 mM silver nitrate solution for 20 
minutes. The gel was moved to the developing solution (0.28 M sodium carbonate, 0.05% 
(v/v) formaldehyde) and agitated for 2 minutes. Fresh developing solution was added and 
the gel agitated until slight yellow background appeared. The gel was placed in stopping 
solution (3% (v/v) acetic acid) for 5 minutes before it was washed twice with deionized 
water and stored. 
2.5.5 Molecular Weight Determination 
Both coomassie blue and silver stained gels were dried using either a Bio-Rad 
model 543 gel dryer (Richmond, CA) or by air drying. The coomassie blue stained gels 
were scanned on an ISCO model 1312 gel scanner and analyzed using a commercially 
available software (Chemresearch Chromatographic Data Management Software, ISCO, 
Lincoln, Nebraska). Using this program, the distance traveled by molecular weight 
standards were plotted against the log of their molecular weight. Using the relation: 
d =blog MW+ c 
where d is the distance traveled by the band, MW is the molecular weight of the standard 
and band care constants, linear fitting was used to determine the values ofb and c. With 
b and c known, the distance of each peptide's band was plugged in the equation to give the 
estimated molecular weight. 
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2.6 Western Blotting 
After running SDS-P AGE or non-denaturing-PAGE, if necessary, gels were 
prepared for blotting by soaking them in the transfer buffer (25 mM Tris, 192 mM glycine, 
20% methanol, pH 7.5). The blotting was done using blotting paper (USB, Cleveland, 
Ohio) at constant voltage of 22 V overnight at 4 °C. After blotting, the blotting papers 
were soaked in TBS buffer (5 mM Tris, 150 mM NaCl, pH 7.4) containing 9% non-fat 
milk with shaking for 1. 5 hours at room temperature. Then blotting papers were soaked 
in the primary antibody solution with shaking for 1.5 hours at room temperature. Two 
different mouse antispectrin monoclonal antibodies (SB-SPl and SB-SP2, Sigma Chemical 
Company, St. Louis, MO) and a rabbit antispectrin polyclonal antibody (Sigma Chemical 
Company) were used throughout the study. Blotting papers were washed with TBST 
(TBS containing 0.05% Tween-20) buffer three times for 5 minutes each. After that 
blotting papers were soaked in the secondary antibody (Goat anti-mouse for SB-SPl and 
SB-SP2 antibodies and Goat anti-rabbit for the polyclonal antibody, Pierce, Rockford, IL) 
with shaking for 1.5 hours at room temperature, and washed 4 times with TBST for 5 
minutes each. After that the developing solution (100 mM Tris, 100 mM NaCl, 5 mM 
MgCl:o 0.4 mM 5-Bromo-4-Chloro-3-Indolyl Phosphate p-Toluidine Salt, 0.4 mM Nitro 
Blue Tetrazolium, pH 9.5) was added, and blotting papers were shaken gently until bands 
appeared to desired intensity, followed by washing twice with deionized water for 2 
minutes each and air drying. 
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2.7 Molecular Weight Calculations 
Molecular weights of spectrin peptides were determined from amino acid contents 
using the program PEPTIDESORT, Genetics Computer Group. Molecular weights of the 
following spectrin peptides: Spcx 1-49, Spcx 1-155, Spcx 1-167, Spcx 1-446, Spcx4 l- l 55, 
Spcx41-167, Spcx41-273, Spcx49-155, Spcx49-167, Spcxl00-255 and Spcxl00-273 were 
found to be 5.8, 18.4, 19.9, 51.7, 13.6, 15.1, 27.3, 12.7, 18.3 and 20.6 kD, respectively. 
The molecular weight ofSpcx 1-166 (S12C) was 19.8 kD. The molecular weight of 26 kD 
for GST was obtained from literature (Smith and Johnson, 1986). The molecular weights 
of fusion proteins were calculated by adding the molecular weight of the spectrin peptide 
to the molecular weight of GST. Molecular weights of ex-and P-spectrin were obtained 
from literature to be 280 (Sahr et al., 1990) and 246 kD (Winkelman et al., 1990), 
respectively. 215, 89, 78, 72, 43 and 35 kD were used as molecular weights of bands 2.1 
(ankyrin), 3, 4.1, 4.2, 5 (actin) and 6 (glyceraldehyde-3-phosphate dehydrogenase), 
respectively (Mathews, C.K. and Van Holde, K.E., 1990). 
2.8 Amino Acid Sequencing 
After running SDS-P AGE, gels were prepared for blotting by soaking in transfer 
buffer (10 mM CAPS, 10% methanol, pH 7.5). The blotting was done using polyvinylidine 
diflouride membranes (Applied Biosystems, Foster City, CA) at 0.15 Amp. for 1 hour. 
The membranes were stained in 0.05% Coomassie Blue solution for 5-10 minutes and 
destained in 40% methanol, 10% acetic acid solution for -10 minutes. They were rinsed 
in deionized water for 2 minutes and left to air dry. The desired bands were excised and 
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sent for amino acid sequencing. 
2.9 Protein Concentration Assay 
Peptide concentration for spin labeled samples was determined by a dye binding 
assay (Bradford, 1976). The dye solution was prepared by diluting the dye reagent 
(Coomassie Brilliant Blue G-250, Bio-Rad, Richmond, CA) five times by adding 4 
volumes of deionized water to one volume of the dye reagent followed by filtering the 
solution through a Whatman filter paper. Five BSA standard solutions were prepared with 
concentrations ranging from 0.2 - 1 mg/ml. 100 µl of protein samples (standards or 
spectrin) were added to 5 ml of the dye solution. These solutions were left to stand at 
room temperature for 5 minutes before the absorbance at 595 run were measured, using 
the dye solution as blank. Absorbance of the standard solutions were plotted against their 
concentrations. Least square linear fit was used to obtain the best fit calibration equation. 




Stability of a-Spectrin Peptides 
Degradation 
Spectrin peptides were tested for degradation by incubating the FPLC purified a-
spectrin peptide at -70, -20, 4, 25 and 35 °C and taking SDS gel electrophoresis samples 
at time zero and after 24 hours. These samples were electrophoresed as described in 
section 2. 5 .1 above. The gel was then studied for any degradation bands. 
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2.10.2 Aggregation 
FPLC purified spectrin peptide samples were incubated at 4 °C for 16-24 hours. 
Non-denaturing gel electrophoresis samples were taken after incubation time. Also, after 
incubation for 16 hours at 4 °C the sample was reloaded on FPLC to check if any 
aggregation bands would appear. 
2. 11 Limited Chymotrypsin Digestion 
Chymotrypsin stock solution was prepared by dissolving 10 mg of 3 X crystallized 
bovine pancreatic a-chymotrypsin (Sigma) into 40 ml of 1 mM HCl solution. The stock 
solution was stored in 200 µl aliquot at -70°C. The FPLC purified spectrin peptide was 
concentrated using centricon micro concentrators (Amicon) to a final concentration of-1 
mg/ml by centrifugation at 2000 xg on a Sorvall RT6000B Refrigerated Centrifuge and 
an A500 rotor. A vial of chymotrypsin was thawed and added immediately to the reaction 
vial in a ratio of 1 µl of chymotrypsin stock solution per 100 µg of spectrin peptide, i.e. 
1 :400 weight ratio. The time of chymotrypsin addition was considered as time zero. At 
t= 0, 15, 30, 60, 90, 120, 150, and 180 minutes, a sample (about 50 µl) was removed, 
equal volume of 2X SDS loading buffer was added and the mixture boiled for 5 minutes. 
The samples were electrophoresed on SDS-P AGE. 
24 
2.12 Spin Labeling and Electron Paramagnetic Resonance of cx-Spectrin 
Peptides 
2.12.1 Spin Labeling 
The sulfbydryl specific nitroxide spin label 4-maleimido-2,2,6,6-tetramethyl-l-
piperidinyloxy (Mal6) was used to spin label a-spectrin peptides. It was purchased from 
Aldrich Chemical Company Inc. (Milwaukee, WI) and used without further purification. 
A 10-2 M stock solution was prepared by dissolving 25 mg of Mal6 in 10 ml of acetonitrile 
and stored at -20°C. 
In order to prepare a-spectrin peptides for spin labeling, PME was added to 3-5 
mg of a-spectrin peptide to give a final concentration of 4 5 mM followed by incubation 
at 4 °C for 30 minutes. The solution was loaded onto a Sephadex G25 gel filtration 
column pre-equilibrated with 5 mM phosphate buffer at pH 7.4 (5P7.4) buffer. The first 
peak containing the spectrin peptide was collected. It was concentrated using centricon 
micro concentrators to a final concentration of -1 mg/ml. The second peak containing 
p ME was discarded. 
The required amount ofMal6 spin label to give a molar ratio of24: 1 to the spectrin 
peptide was transferred into a brown vial. Acetonitrile was removed by passing a very 
gentle stream ofN2 gas to give a thin film of the spin label on the surface of the vial. The 
spectrin peptide at 1 mg/ml was added to the vial and incubated at 4 ° C for 15 hours with 
gentle stirring. After that, the mixture was loaded on the Sephadex G25 column pre-
equilibrated with 5P7.4 buffer. The first peak containing the spin labeled peptide was 
collected while the second peak containing the free spin label was discarded. The spectrin 
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peptide was concentrated using centricon micro concentrators to a final concentration of 
10-4 -10-5 M. EPR samples were prepared by pipetting 20 µl of the spin labeled peptide 
into a capillary tube. One end was sealed using a flame and centrifuged using an EIC 
MICRO HEMATOCRIT MB CENTRIFUGE (DAMON IEC DIVISION, Needham 
Heights, Mass) to push all sample to the sealed end. 
2.12.2 Electron Paramagnetic Resonance (EPR) 
EPR was done on a Varian E-Line Century series EPR spectrometer coupled with 
a Zenith personal computer. A commercially available software program, Assyst 
(MacMillan Software) modified for EPR operation, was used for data acquisition and 
analysis. Parameters used were: incident microwave power, 2 mW; center of the field, 
3242.5 gauss; scan range, 100 gauss; modulation amplitude, 1 gauss; time constant, 0.128; 
receiver gain, 1 x 104; scan time, 60 seconds. All experiments were done at room 
temperature (-21°C). The spin labeled samples prepared as above were placed inside a 
quartz tube containing silicon fluid situated within the cavity. Samples were left for 5 
minutes in the cavity to equilibrate to room temperature before EPR spectrum were 
obtained. Spin label concentration was determined by double integrating the EPR spectra. 
Using the protein concentration assay mentioned above, the spectrin peptide concentration 
was determined. Finally, the spin label to peptide molar ratio was calculated. 
2.12.3 Calculations of the Rotational Correlation Time 
The rotational correlation time was calculated using the equation: 
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where ho is the amplitude of the middle peak, h_, is the amplitude of the high field 
peak, h+1 is the amplitude of the low field peak and W0 is the peak-to-trough distance of 
the center line (Fung and Johnson, 1984). 
2.13 
2.13.1 
Purification of P-Spectrin Subunit 
Preparation of Spectrin-Actin Network From Human Red Blood Cells 
Packed red blood cells were obtained from a local blood bank (LifeSource). Up 
to 120 ml of the packed red blood cells was used in each experiment. In each of 50 ml 
centrifuge tubes, 5 ml of the packed red blood cells were placed and PBS7.4 buffer was 
added. The tubes were centrifuged at 2000 xg for 4 minutes in a Sorvall R T6000B 
centrifuge. The supernatant along with the huffy coat were aspirated, discarded and fresh 
PBS7.4 buffer was added. The centrifugation was repeated at least twice until a 
completely clear supernatant was obtained. A low ionic strength buffer ( SmM phosphate, 
lmM EDTA, pH 8.0) was added to the washed cells and centrifuged with SA600 rotor 
at 16000 rpm for 10 minutes in Sorvall RC-SB centrifuge. The supernatant along with the 
button at the bottom were aspirated and discarded and fresh buffer was added to the pellet. 
The washing was repeated until the supernatant cleared completely of hemoglobin. The 
white pellets from all tubes were combined and a 100 µl electrophoresis sample was taken. 
Then 5 - 10 volumes of0.1 mM EDTA, 0.5 mM PME, 0.2 mM PMSF, pH 9.0 solution 
was added and the mixture incubated at 37°C for 30 minutes. The solution was 
centrifuged at 22000 rpm for 60 minutes at 4 °C in an OTD65B Sorvall Ultracentrifuge 
(Du Pont Instruments, Wilmington, D.E.) with T865 rotor. The supernatant (spectrin-
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actin network) was collected and the pellet discarded. 
2.13.2 Preparation of Spectrin Dimer and Tetramer 
The spectrin-actin was concentrated to -10 ml using Stirred Cells with a YM I 00 
Disc Membrane. A I 00 µl electrophoresis sample was taken. The concentrated spectrin-
actin was loaded onto a Superose 6 column pre-equilibrated with 5P7.4 buffer and ran at 
20 ml/hour. The first and the second peak containing the spectrin tetramer and dimer, 
respectively, were collected and concentrated using Stirred Cells with a YMIOO Disc 
Membranes. 
2.13.3 Purification of (3-Spectrin From Spectrin-Actin Network 
2.13.3.1 Purification of (3-Spectrin Using DE-52 Column 
2.13 .3 .1.1 Purification of P-Spectrin Using Published Procedure 
Published procedure was used to purify (3-spectrin (Speicher et al., 1992). The 
spectrin-actin was concentrated to - 100 ml at - 0.6 mg/ml using Stirred Cells with a 
YM 100 Disc Membranes. A 100 µl electrophoresis sample was taken. The concentrated 
spectrin-actin was treated with solid urea, PME and IOX buffer (200 mM Tris, 1.5 M 
NaCl, 10 mM EDT A, pH 8.2) to give a final concentration of 3M urea, 150 mM NaCl, 20 
mM Tris, 1 mM EDTA and 0.6 mM PME. This solution was mixed batchwise with DE-
52 resin (Whatman, Fairfield, NJ) pre-equilibrated with 18 mM Tris, 3M urea, 135 mM 
NaCl, 0.9 mM EDTA and pH 8.2 buffer (300 ml of resin per 100 mg of spectrin-actin). 
The mixture was incubated for one hour at 4 °C before the solution was eluted with a flow 
rate of 150 ml per hour. Three buffers with increasing NaCl concentrations were used to 
elute proteins. The first one contained 152 mM NaCl and used to elute actin and other 
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weakly bound contaminants. The second buffer contained 181 mM NaCl and used to elute 
p-spectrin. The third contained 234 mM NaCl and used to elute a-spectrin. The P-
spectrin fraction was concentrated using Stirred Cells with YM 100 Disc Membranes. The 
concentrated sample was dialyzed three times against isotonic KCl buffer ( 10 mM Tris, 20 
mM NaCl, 130 mM KCl, 1 mM pME, 30 µM PMSF, pH 7.4). 
2.13.3.1.2 Purification of P-Spectrin Using Modified Procedure 
The published procedure described above did not give P -spectrin with the purity 
anticipated. The procedure was modified by using 135 mM NaCl to elute actin and other 
weakly bound contaminants, 170 mM NaCl to elute P-spectrin and 500 mM NaCl to elute 
a-spectrin. 
2.13.3.2 Purification of P-Spectrin Using FPLC and Mono Q HR.10/10 Column 
The spectrin-actin supernatant was concentrated to - 25 ml using Stirred Cells 
with a YMIOO Disc Membranes and treated with urea buffer as above. The solution was 
then incubated for 60 minutes at 4 °C and filtered through 0.22 µm filter and loaded onto 
a Mono Q HR.I 0/10 anion exchange column of the FPLC system. The buffer system 
consisted ofbuffer A(18 mM Tris, 250 mMNaCl, 0.9 mM EDTA, 3M urea, pH 8.2) and 
buffer B (18 mM Tris, 400 mM NaCl, 0.9 mM EDT A, 3M urea, pH 8.2). The following 
procedure was to purify P-spectrin: 50 ml buffer A to elute actin and other weakly bound 
proteins. The gradient was increased to 287.5 mM NaCl after 10 ml and remained at that 
concentration for 40 ml to elute P-spectrin. After that, buffer B was used to elute a-
spectrin. The flow rate used was 2 ml/min. 
The P-spectrin peak at 100 mM NaCl was collected and concentrated using Stirred 
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Cells with YMlOO Disc Membranes and/or centricon micro concentrators. P-spectrin was 
dialyzed three times against isotonic KCl buffer (10 mM Tris, 20 mM NaCl, 130 mM KCl, 
1 mM PME, 30 µM PMSF, pH 7.4) and used immediately or stored at 4 °C. 
2.14 
2.14.1 
Stability of P-Spectrin 
Degradation at 4 ° C 
Stability of P-spectrin was done by incubating J3-spectrin at 4 °C for 6 days. Gel 
electrophoresis samples were taken at each day and stored at -20°C until all samples were 
collected. SDS-PAGE was done on these samples. 
2.14.2 Degradation at -70°C 
Stability of 13-Spectrin was performed by taking a gel sample before freezing J3-
spectrin at -70°C for 3 months. After thawing the stored sample, another gel 
electrophoresis sample was taken. SDS-PAGE was done on both samples. 
2.14.3 Aggregation at -70°C 
This experiment was done as described above for the degradation except that non-
denaturing PAGE was done. 
2.15 
2.15.1 
Radiolabeling of cx-Spectrin Peptides With 1251 
Time Study 
The time study was done according to literature supplied by the company (Pierce, 
Rockford, IL) in order to determine the labeling time that would give maximum labeling 
and minimum degradation. 0.1 mCurie of 125I (1 µl) was added to 1 bead ofIODO-BEAD 
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(Pierce, Rockford, II) in 100 µl oflabeling buffer (100P6.5). After stirring for 5 minutes 
10 µg of Spa41-273 were added. At 0, 1, 2, 4, 8, and 16 minutes, 5 µl sample was taken 
and added to 1 ml of PBS containing 0.5 mg/ml BSA. Each of the 6 samples was diluted 
1:10 with 20 mM Tris, 1 mMEDTA, 0.5 mg/ml BSA, pH 7.4 by taking 100 µl of sample 
into 900 µl of buffer. To the diluted samples, 100 µl of 60% trichloroacetic acid (TCA) 
was added and the solution centrifuged. The supernatant from each sample was removed 
into scintillation tubes. Fresh 50 µl of 60% TCA was added to the pellet and the solution 
was again centrifuged. The supernatant was discarded and the pellets were placed into 
scintillation tubes. Gamma counter (the Department of Biology) was used to count the 
1251 in pellet and supernatant samples. Table 1 shows counts per minute for the pellet 
samples. 
The counts per minute shown in Table 1 were plotted using the origin program 
(Microcal, Northampton, MA) against time and shown in Figure 1. Figure 1 shows counts 
per minute were maximum after 2 minutes of iodination. This indicates that iodination of 
the spectrin peptide was maximum after 2 minutes, after which the peptide starts to 
degrade under the reaction conditions. Thus all iodination for immunoprecipitation 
experiments were done for 2 minutes to maximize iodination and minimize degradation of 
spectrin peptides. 
2.15.2 Radio labeling 
To activate 1 mcurie of the 1251, 1 bead ofIODO-BEAD was added to the solution 
followed by the labeling buffer (100 mM phosphate, pH 6.5) to 300 µ1 total volume. The 
solution was stirred for 5 minutes and 100 µg of the spectrin peptide was added. The 
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Table 1: Counts per minute for pellets for time study 









Iodination time study. Counts per minute of the pellets vs. minutes 




























































mixture was then stirred for 2 minutes at room temperature before loading it onto 
Sephadex G25 column pre-equilibrated with the labeling buffer. 1 ml fractions were 
collected and counted. These counts per minute were plotted against tube number (Figure 
2). The first peak contains the radiolabeled Spa 1-167 and the second one contains the 
excess or free iodine. Tubes containing the radiolabeled peptide were determined from the 
plot and grouped. The radiolabeled peptide was then dialyzed 3 times against isotonic KCl 
buffer to further remove free iodine. Under reaction conditions, only tyrosine residues 
would be labeled with iodine. According to the amino acid sequence of a-spectrin, the 
peptide Spa 1-167 contains 5 tyrosine residues at positions: 35, 53, 81, 91, and 163. 
2.16 
2.16.1 
Stokes Radius Determination 
Column Calibration 
A Superose 6 column attached to FPLC system was used to study the Stokes radii 
of spectrin peptides. Before conducting the study, it was necessary to calibrate the 
column. Table 2 below show the 6 standard proteins (Pharmacia Biotechnology, 
Piscataway, NJ) that were used to calibrate the column. 
The Superose 6 column was pre-equilibrated with isotonic KCl buffer before 
loading each of the 6 standard proteins. A flow rate of 0.20 ml/min was used to pass 30 
ml of buffer through the column. The elution volume for each standard protein was 
calculated. 
2.16.2 Stokes Radius Calculations 
The partition coefficients CK.av) for standards and samples were calculated using the 
Figure 2: 
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Radiolabeling of the spectrin peptide Spa 1-167 with 1251. Counts 

















































Table 2: Molecular weights (MW) and Stokes radii (~) of standards 
used in Superose 6 calibration 
PROTEIN MW(kD) 
Thyroglobulin 669 85.0 
Ferritin 440 61.0 
Catalase 232 52.2 
BSA 67 35.5 
Ovalbumin 43 30.5 
Chymotrypsinogen 25 20.9 
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equation~.= (V.-V0)/(VcV0), where Ve is the elution volume, V0 is the void volume and 
Vt is the total bed volume. v. is determined from the elution profile, V0 and Vt were 
supplied by the company. K.i.. values for the standards were plotted against the log of the 
Stokes radius (log (RJ). Linear regression was used to obtain the best fit for the equation 
log (Rj = a K.i.. + b. After determining the constants a and b from standards, the equation 
was used to calculate Stokes radii of spectrin samples. 
2.17 
2.17.1 
Binding Assays of a-Spectrin Peptides Binding with P-Spectrin 
Gel Filtration Assay 
FPLC purified Spa 1-166 (S12C), Spa 1-167, spectrin-actin and P-spectrin subunit 
were used in this study. All samples were dialyzed in isotonic KCl buffer before starting 
the experiment. Spa 1-166 (S12C) or Spa 1-167 (1.15 x 10-6 Meach) was mixed with P-
spectrin (2.7 x 10-7 M) and incubated for 24 hours at 4 °C. Control samples of Spa 1-166 
(S 12C), Spa 1-167 or P-spectrin were prepared by adding the appropriate volume of 
isotonic KCI buffer and incubated for 24 hours. After 24 hours, the incubation mixture or 
control samples were loaded onto the Superose 6 column pre-equilibrated with the 
isotonic KCI buffer. The same program used above for standards was used to obtain 
elution profiles for the mixture and control samples. Kav was calculated and the Stokes 
radii determined using the calibration curve. The Stokes radii were compared to check for 
any change between incubation and control samples. 
Binding constants were calculated by using the following equations: 
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a-Sp + P-spectrin a-Sp-J}-spectrin (complex) 
with the binding constant (Ka): 
Ka= [a-Sp-P-spectrin]/ ([a-Sp][P-spectrin]) 
The area of the spectrin peptide of control and incubated samples were calculated. 
The area of a peak was calculated by taking the two slopes and the base as a triangle and 
using the equation 
A= 1/2 x bx c 
where A is the area of the peak, bis the length of the base and c is the height of the 
peak (base to head of triangle). The percent of peptide remained was calculated by 
dividing the area of the incubated sample by the area of the control sample. This percent 
was multiplied by the initial concentration of the peptide to give the equilibrium 
concentration of the peptide. The concentration of the complex was calculated by 
subtracting the final from the initial concentration of the spectrin peptide. The equilibrium 
concentration of P-spectrin was calculated by subtracting the concentration of the complex 
from the initial concentration of P-spectrin. 
2.17.2 Combined Western Blotting With Radiolabeling 
P-spectrin was incubated with the radiolabeled peptide Spa 1-167 to give final 
concentrations of9 x 10·7 and 3.5 x 10-7 M, respectively. Control samples of Spa 1-167 
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were prepared by adding the appropriate volume of isotonic KCl buffer. All samples were 
incubated for 24 hours at 4 °C. After that samples were ran on 7% non-denaturing PAGE. 
After Western blotting with the SB-SPl antibody, the stained bands (contained both P-
spectrin and complex) and areas where the Spa 1-167 usually appeared were excised and 
counted. 
In order to determine the binding constant, the ratio of unbound to the total Sp a 1-
167 was calculated (counts per minute of the Spa 1-167 divided by the total counts per 
minute). The equilibrium concentration of Spa 1-167 was calculated by multiplying the 
initial concentration of the peptide by the ratios. The concentration of the complex was 
calculated by subtracting the final from the initial concentration of the peptide. The 
concentration of P-spectrin was calculated by subtracting the concentration of the complex 
from the initial concentration of P-spectrin. The binding constant was then determined 
from the equilibrium concentrations of the three components using the binding constant 
equation (section 2.17.1). 
2.17.3 Immunoprecipitation 
P-spectrin was incubated with the radiolabeled Spa 1-167 to give final 
concentrations of 3.3 x 10-7 Mand 1.26 x 10-6 M, respectively. Control samples were 
prepared by adding appropriate volumes of isotonic KCl buffer to give a final volume of 
5 µl. All samples were incubated for 36 hours at 4°C. Then 30 µg of the SB-SPl 
antibody and 22 µl of immunoprecipitation buffer (20 mM Tris, 150 mM NaCl, 1 % Triton 
X-100, 1 % sodium deoxycholate, 0.1% SDS, pH 7.5) were added and the solution 
allowed to incubate for 1 hour at 4°C. Then 30 µl of Pansorbin (CalBiochem, San Diego, 
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CA) were added, and the mixture was incubated for 30 minutes at 4 °C. The solution was 
centrifuged at 15000 g for 3 minutes and the supernatant collected. The pellet was washed 
3 times with 1 ml immunoprecipitation buffer by centrifugation at 15000 g for 3 minutes. 
The 1251 in pellet and supernatant were counted and the counts per minute are summarized 
in (table 3). 
The binding constant was calculated by first determining the ratio of bound Spa 1-
167 from the total Spa 1-167. The ratio was determined by dividing the counts per minute 
of the pellet by the total counts per minute of both pellet and supernatant followed by 
subtracting the background ratio (control samples). The equilibrium concentration of the 
complex was calculated by multiplying the ratio by the initial concentration of Sp a 1-16 7. 
The concentration of the unbound Spa 1-167 was caculated by subtracting the 
concentration of the complex from the initial concentration of the peptide. The 
concentration of P-spectrin was calculated by subtracting the complex concentration from 
the initial P-spectrin concentration. The binding constant was calculated from the 
equilibrium concentrations of the three components using the binding constant equation 
(section 2.17.1 ). 
Table 3: Concentrations and molar ratios of Spa 1-167 and P-spectrin used in 
immunoprecipitation experiments (Total volume, 18 µl) 
Spal-167 P-Spectrin 
(µmoles) 6.3 x 10-6 1.7 x 10-6 
Concentration (M) 1.2 x 10-6 2.7xl0-7 
Molar Ratio 1 0.3 
CHAPTER III 
RESULTS 
3.1 Expression, Purification and Stability of GST and a-Spectrin Peptides 
3 .1.1 Expression of GST and Spectrin Peptides as GST-Fusion Proteins 
The HB101 E. coli cells were induced for the production of the fusion protein: 
GST-Spcxa-b, where GST is glutathione-S-transferase, Spa is cx-spectrin, a is the amino 
acid residue number in intact spectrin of the first amino acid in the peptide and b is the 
amino acid residue number in intact spectrin of the last amino acid in the peptide. Cells 
containing vectors of twelve different fusion proteins were prepared by Dr. Kelley: GST-
Spcx 1-49, GST-Spa 1-155, GST-Spcx 1-166 (S12C), GST-Spcx 1-167, GST-Spcx 1-446, 
GST-Spcx41-155, GST-Spcx41-167, GST-Spcx41-273, GST-Spa49-155, GST-Spcx49-
167, GST-Spcx 100-255 and GST-Spcx 100-273. These fusion proteins were expressed to 
produce Spcxl-49, Spcxl-155, Spal-166 (S12C), Spal-167, Spcxl-446, Spa41-155, 
Spa41-167, Spa41-273, Spa49-155, Spa49-167, Spa 100-255 and Spa 100-273. 
SDS polyacrylamide gel electrophoresis results show that expressed proteins in 
cells have correct molecular weights. Figures 3a show the results for GST-Spa 1-166 
(S 12C). Lane 1 show the molecular weight standards. Lane 3 show the whole cell extract 




SDS polyacrylamide electrophoresis gels (12%) stained with 0.05% 
Coomassie brilliant blue R. These gels (0. 75 mm thick) were run 
for about 40 minutes under a constant voltage of 160 V. Lane 1 in a, 
band c: low molecular weight standards; lane 2: total cell extract of 
E.coli HBlOl without IPTG induction; lane 3: total cell extract of E. 
coli HB 101 with IPTG induction for the production of the fusion 
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cell extract of E. coli without induction for the production of the fusion protein. The 
molecular weight of the induced band was estimated using the molecular weight standards 
as a reference and found to be 45 kD. Similarly, lane 3 in Figs. 3b and 3c showed induced 
bands for the induction of GST-Spa 100-255 and GST-Spa 100-273 with estimated 
molecular weights of 27 and 27 kD, respectively. The calculated molecular weights of 
these fusion proteins were: 46, 44 and 47 kD, respectively. This shows that calculated 
molecular weight matched the estimated value for GST-Spa 1-166 (S 12C) and not GST-
Spa 100-255 or Spa 100-273. As shown above, calculated molecular weights for Spa 100-
255 and Spa 100-273 were 44 and 47 kD while the observed molecular weights were 27 
and 27 kD, respectively. This molecular weight corresponds to GST and hence indicates 
that DNA ligation was not successful and that the cells did not express the fusion proteins. 
Several other attempts to express these two fusion proteins were not successful. Nine of 
the proteins (GST-Spal-49, GST-Spal-155, GST-Spal-167, GST-Spal-446, GST-
Spa41-155, GST-Spa41-167, GST-Spa41-273, GST-Spcx49-155 and GST-Spcx49-167) 
were done by other members in our laboratory. 
3 .1.2 Purity of GST and GST-Fusion Proteins 
Fusion proteins were affinity purified from cell lysate with an average yield of 0.5-
7.0 O.D. values per liter of E. coli cell culture for all nine expressed fusion proteins except 
for Spcxl-166 (S12C) which gave 10-15 O.D. units per liter. Some of these affinity 
purified fusion proteins showed however other bands of lower molecular weights. Lanes 
2 and 3 in Fig. 4a show SDS-PAGE of GST-Spcx 1-167 and Spa41-167, respectively, 
while lane 1 shows molecular weight standards. Lane 2 in Figs. 4b, and 4c shows SDS-
Figure 4: 
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SDS polyacrylamide electrophoresis gels (12%) stained with 0.05% 
Coomassie brilliant blue R. These gels (0. 75 mm thick) were run for 
about 40 minutes under a constant voltage of 160 V. Lane 1 in (a), 
(b) and (c): molecular weight standards. Lane 2 in (a), (b) and (c): 
glutathione affinity purified GST-Spa 1-167, GST-Spa 1-166 (S l 2C) 
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PAGE of GST-Spa 1-166 and GST-Spa4 l-273, respectively, while lane 1 shows 
molecular weight standards. The molecular weights of the fusion proteins: GST-Spa 1-49, 
GST-Spal-155, GST-Spal-166(S12C), GST-Spal-167, GST-Spal-446, GST-Spa41-
155, GST-Spa41-167, GST-Spa41-273, GST-Spa49-155 and GST-Spa49-167 were 
estimated to be 31±1, 41±2, 45 ± 2, 45 ± 2, 78 ± 4, 40 ± 2, 39 ± 1, 53 ± 2, 37 ± 2 and 
39 ± 2 kD, respectively. Table 4 below show the estimated and calculated molecular 
weights for these peptides. 
In order to determine the best time for maximum thrombin digestion without 
exposing the peptide to degradation fusion proteins above were loaded onto thrombin 
column. Electrophoresis samples were taken between 0 and 31 hours from the start of 
incubation and run on SDS-PAGE. It was found that after 24 hours the fusion proteins 
were mostly digested. Figure 5 below shows SDS-P AGE with samples at 0 and 24 hours 
(lanes 2 and 3, respectively). At 0 hours a major band with estimated molecular of 45 kD 
that matches that of the fusion protein could be seen in addition to other bands with lower 
molecular weight. After 24 hours the 45 kD band disappeared while a much fainter band 
with estimated molecular weight of 15 kD appeared indicating the digestion of the fusion 
protein and the production of the spectrin peptide. 
3. 1. 3 Purity of 9 a-Spectrin Peptides Purified With Glutathione Affinity 
Nine glutathione affinity purified peptides (Spa 1-155, Spa 1-166 (Sl2C), Spa 1-
167, Spa 1-446, Spa41-155, Spa41-167, Spa41-273, Spa49-155 and Spa49-167) were 
used in this study. Six were used to determine the start of the structural domain of 
spectrin. Spal-166 (S12C), Spal-167 and Spa41-273 were used in the study of the 
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Table 4: Estimated and Calculated molecular weights of a-spectrin peptides in kD. 
FUSION PROTEINS ESTIMATED MW CALCULATED MW 
GST-Spa 1-49 31 32 
GST-Spa 1-155 41 44 
GST-Spal-166 (Sl2C) 45 46 
GST-Spa 1-167 45 46 
GST-Spal-446 78 78 
GST-Spa41-155 40 40 
GST-Spa41-167 39 41 
GST-Spa4 l-273 53 53 
GST-Spa49-155 37 39 
GST-Spa49-l 67 39 40 
Figure 5: 
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SDS polyacrylamide electrophoresis gel (16%) stained with 0.05% 
Coomassie brilliant blue R. This gel (0. 75 mm thick) was run for 1 
hour under a constant voltage of 160 V. Lane I: low molecular weight 
standard; lanes 2 and 3: GST-Spa4 l-167 incubated on the thrombin 
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head-to-head interactions. Glutathione affinity purified spectrin peptides were tested for 
their purity on SDS-PAGE. Lane 2 in Figs. 6a, 6b, 6c and 6d show SDS-PAGE of the 
affinity purified a-spectrin peptides Spal-166 (S12C), Spal-167, Spa41-167 and 
Spa41-273, respectively. Lane 1inFigs6a-6d show the molecular weight standards. All 
of the nine peptides purified by glutathione affinity exhibited one major band on SDS-
p AGE with molecular weights matching the calculated MW for these peptides. Minor 
bands with estimated molecular weights that matches these of GST and corresponding 
fusion protein were also detected (Fig. 6). Densitometric tracing show the intensity of the 
major bands to be 60-95% of the total intensity in each sample. 0.5 - 5 O.D. units of 
affinity purified spectrin peptides were obtained per 10 O.D. units of fusion protein loaded 
on the thrombin column. 
3.1.4 
3.1.4.1 
Fast Protein Liquid Chromatography (FPLC) Purified a-Spectrin Peptides 
Assignment of GST Peak Using Affinity Purified GST Protein 
Glutathione affinity purified GST was loaded onto Mono Q column. FPLC elution 
profiles show two peaks. The first peak appears at 118 ± 14 mM NaCl and could not be 
concentrated using a centricon-3 (3K MWCO) micro concentrator indicating molecular 
weight ofless than 3000 kD. The second peak appears at 228 ± 4 mM NaCl and exhibited 
as a single band on SDS-PAGE with molecular weight of26 kD, indicating that this was 
the GST peak, obtained from literature. 
3.1.4.2 Purity of Mono Q HRl0/10 Purified a-Spectrin Peptides 
The net charges of the spectrin peptides Spa 1-49, Spa 1-166(S12C), Spa 1-167, 
Spa 1-446, Spa41-155, Spa41-167 and Spa49-167 were determined from the program 
Figure 6: 
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SDS polyacrylamide electrophoresis gels (16%) stained with 0.05% 
Coomassie Brilliant Blue R. These gels (0. 75 mm thick) were run for 
about one hour under a constant voltage of 160 V. Lane 1 in a, b, 
c and d show the molecular weight standards; lane 2 in a, b, c and d 
show the glutathione affinity purified Spa 1-166 (S12C), Spa 1-167, 








































PEPTIDESORT to be-1, -s, -s, -33, -6, -5 and -7, respectively. These charge values 
could be grouped into three groups: the first contains peptide of 1 negative charge Spa 1-
49; the second contains peptides of 5 to 8 negative charges Spa 1-166(S12C), Spa 1-167, 
Spa41-155, Spa41-167 and Spa49-167 and the third contains peptide of 33 negative 
charges Spa 1-446. Thus different salt concentrations were used for purifications. Figure 
7a and 7b showFPLC elution profile for the purification of Spa 1-166 (S12C) and Spa 1-
167. Both Spa 1-166 (S12C) and Spa 1-167 were eluted at about 125 mM NaCl. Lane 
2 in Figs. 8a and 8b show SDS-PAGE ofFPLC purified Spa 1-166 (Sl2C) and Spa 1-167 
respectively, while lane 1 shows molecular weight standards. These gels show both bands 
with estimated molecular weights of 20 kD, as expected. Figure 9a and 9b show the 
densitometric tracing ofFPLC purified Spa 1-166 (Sl2C) and Spa 1-167 which show one 
peak for each peptide. 
During the FPLC purification of these peptides, when the salt concentration 
increased sharply to 500 mM NaCl, a second peak, accounting for up to 80% of the total 
eluted O.D. units, appeared. SDS-PAGE revealed that this peak consisted of Spa 1-166 
(S12C) peptide, GST and the GST-Spa 1-166 (S12C). 
3.1.5 
3.1.5.1 
Stability of a-Spectrin Peptides 
Stability of a-Spectrin Peptides From Degradation 
Spa49-167 incubated at -10, -20, 4 and 25°C for 24 hours did not show any sign 
of degradation. At 35 °C, a faint band of lower molecular weight appeared (molecular 
weight estimated to be 13 kD). 
Figure 7: 
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FPLC elution profile from Mono Q HRl0/10 column using a flow rate 
of2 ml/min and sensitivity of 10 mV. a: the purification of Spa 1-166 
(Sl2C); b: the purification of Spa 1-167. 
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SDS polyacrylamide electrophoresis gels (16%) stained with 0.05% 
Coomasssie Brilliant Blue R. These gels (0. 75 mm thick) were run for 
about 1 hour under a constant voltage of 160 V. Lane 1 in a and b 
show the molecular weight standards; lane 2 in a and b show the FPLC 
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Densitometric tracing of SDS polyacrylamide electrophoresis gels 
stained with 0.05% Coomassie Brilliant Blue R. a: FPLC purified 
Spa 1-166 (S12C). b: FPLC purified Spa 1-167. 
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3.1.5.2 Stability of a-Spectrin Peptides From Aggregation 
Spa49-167 incubated for 16 hours at 4°C exhibit ~ 5% aggregation, smce 
reloading sample to FPLC Mono Q column resulted in an elution profile with a major peak 
and minor peaks (about 5%) eluted at 500 mM NaCl. 
3.2 Purity and Stability of P-Spectrin Subunit 
3.2.1 Analysis ofMembrane Samples on SDS-PAGE 
0.76 ± 0.1(n=29) ml of white membranes were obtained per ml of packed human 
red blood cells. Lane 1 in Fig. 10 shows SDS-Polyacrylamide gel electrophoresis of 
membrane sample showing 7 main bands. These 7 bands were identified from literature 
(Mathews, C. and Van Holde, KE., 1990) to be 1: spectrin (a-subunit); 2: spectrin (P-
subunit); 3: band 3; 4: band 4.1; 5: band 4.2; 6: actin; 7: glyceraldehyde-3-phosphate 
dehydrogenase. In the literature, they are usually labeled bands 1, 2, 3, 4. 1, 4. 2, 5 and 6. 
3.2.2 Analysis ofExtracted Spectrin-Actin Samples on SDS-PAGE 
Typically 1.2 ± 0.3 (n = 29) mg of spectrin-actin network were obtained per ml of 
membrane or 0.8 ± 0.2 (n = 73) mg of spectrin-actin network per ml of packed red blood 
cells. Lane 2 in Fig. 10 shows SDS-P AGE of a spectrin-actin sample which shows that 
only spectrin (a- and ~-subunits with approximately 1: 1 ratio), band 4.1 and actin. 
3.2.3 Purity of P-Spectrin Subunit 
3.2.3.1 Purified on DE-52 Column 
In our hands, using published salt gradient with 152 mM (to elute actin), 181 mM 
(to elute P-spectrin) and 234 mM (to elute a-spectrin) NaCl did not produce desirable 
Figure 10: 
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SDS polyacrylamide gel (7%) stained with 0.05% Coomassie Brilliant 
Blue R. This gel was run for about 40 minutes under constant voltage 
of 160 V. Lane 1 : human red blood cell membrane; lane 2: spectrin-
actin sample; lane 3: 135 mMNaCl eluted peak; lane 4: 181 mM NaCl 
eluted peak; lane 5: 234 mM NaCl eluted peak. 
67 
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results. The peaks eluted with 135 or 152 mM NaCl buffer showed bands of actin, 4.1, 
P-spectrin and other proteins, as shown by SDS-PAGE (Figure 10). Lane 3 shows the 
peak at 181 mM NaCl sample which shows a-spectrin band in addition to the P-spectrin 
band. Densitometric tracing showed the percent area of a-spectrin to be 51 ± 10% and 
P-spectrin to be 16 ± 5 % with some degradation bands accounting for the rest of the area. 
The percent ratio of a- to P- spectrin bands was determined to be 24:76%. Lane 4 shows 
the 234 mM NaCl peak sample which shows one band corresponding to a-spectrin 
subunit. Densitometric tracing showed the percent area for a-spectrin to be 100% with 
no detection of P-spectrin or any other protein. Using this weak anion exchange column 
and under these published conditions, P-spectrin subunit could not be purified completely 
free of a-spectrin while a-spectrin was eluted as a pure subunit. The published method 
used four gel filtration columns in a series in the HPLC system. 
This salt gradient was modified to 135 mM, 165 mM and 234 mM NaCl. It was 
found that the 135 mM NaCl buffer was sufficient to elute actin and other weakly bound 
proteins. Some P-spectrin eluted at this salt concentration. Densitometric tracing showed 
26% of P-spectrin and 38% of actin. The peak eluted with the 165 mM buffer showed 
the P-spectrin as the major band (88 ± 4% (n = 5)), and a-spectrin as a very faint band (8 
± 3% (n = 5). Thus the ratio of P-spectrin to a-spectrin is about 90: 10. Although this 
ratio is better than that obtained following the published salt gradient, P-spectrin is still not 
completely purified. 
3.2.3.2 Purified on Mono Q HRl 0/10 Column 
Purification using a Mono Q HRl Oil 0 anion exchange column and a salt gradient 
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produced three peaks at 250 mM, 287.5 mM and 400 mM NaCl (Fig. 11). The first peak 
contained actin (36%), band 4.1 (4%) and other proteins as shown by SDS gel data (Fig. 
12, lane 2). The second peak contained only P-spectrin (~100%) as shown by SDS gel 
data (Fig. 12, lane 3) and analysis of densitometric tracings (Fig. 13). The third peak 
contained a- (78%) and P- (16%) spectrin. Thus the ratio of the P-spectrin to the a-
spectrin in peak 3 was 83:17. About 0.06 ± 0.02 (n = 40) mg of P-spectrin was extracted 
from 1 mg of spectrin-actin. About 0.04 ± 0.02 (n = 41) mg of P-spectrin was extracted 
from 1 ml of packed cells. 
3.2.4 
3.2.4.1 
Stability of P-Spectrin 
Degradation of P-Spectrin at 4 °C 
p-spectrin incubated in the presence of PMSF (serine protease inhibitor) at 4 °C 
showed no significant degradation even after 6 days, as seen by SDS-gel data. However, 
incubating P-spectrin for 6 days without the presence of PMSF showed 70% decrease in 
P-spectrin. 
3.2.4.2 Degradation of P-Spectrin From Freezing and Storage at -70°C 
Freezing P-spectrin at -70°C, for up to 3 months, produced about 10% decrease 
in P-spectrin. 
3.2.4.3 Aggregation of P-Spectrin at 4 °C 
P-spectrin was tested for aggregation at 4°C by running non-denaturing-PAGE 
on P-spectrin samples incubated at 4 °C for 1 to 4 days. These samples were compared 
with spectrin-actin samples. P-spectrin appeared as one major band just below the 
spectrin dimer band. No decrease in the intensity of the P-spectrin band was observed. 
Figure 11: 
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FPLC elution profile from a Mono Q HR.10/10 column at a flow rate 
of2 ml/min and sensitivity of 10 mV. FPLC purification of P-spectrin 
by increasing the salt concentration from 250 to 400 mM NaCl passing 
by 288 mM NaCl where P-spectrin was eluted. 











SDS polyacrylamide electrophoresis gel (7%) stained with 0.05% 
Coomassie Brilliant Blue R. The gel (0. 75 mm thick) was run for 
about 40 minutes under a constant voltage of 160 V. Lane 1: human 
red blood cell membrane; lane 2: peak eluted at 250 mM NaCl; lane 
3: peak eluted at 287.5 mM NaCl; lane 4: peak eluted at 400 mM 
NaCl. 
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Densitometric tracing of SDS electrophoresis gel (7%) stained with 
0.05% Coomassie Brilliant Blue R. The second peak on the FPLC 
elution profile eluted at 287.5 mM NaCl salt concentration. 
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Thus little aggregation of FPLC purified P-spectrin was observed after 4 days at 4 °C. 
FPLC or DE-52 purified P-spectrin were loaded and ran on the Superose 6 column. 
FPLC purified P-spectrin elute as one peak on the elution profile with Stokes radius ( 133 
A), smaller than that of spectrin dimer, and assumed to be that of P-spectrin. However, 
after incubating P-spectrin for five days at 4 °C, a small peak appeared at the void volume. 
On the other hand, DE-52 purified P-spectrin elutes just after the void volume and has 
much higher molecular weight than that of the spectrin dimer. 
3.2.4.4 Aggregation of P-Spectrin at -70°C 
P-spectrin samples frozen at -70°C for about 2 months exhibit little aggregation 
as demonstrated by the elution profile of Superose 6, showing one peak with the same 
Stokes radius obtained before freezing the sample. 
Thus we have developed methods to obtain stable P-spectrin and a-spectrin 
peptides. 
3.3 Spectrin Domain Structure 
The spectrin peptides Spa 1-155, Spa 1-167, Spa 1-446, Spa41-155, Spa41-167, 
Spa41-273, Spa49-155 and Spa49-167 were used in limited chymotrypsin digestion 
study. This work was done with other members in the lab and published. Refer to the 






Binding of a-Spectrin Peptides to P-Spectrin Subunit 
Gel Filtration Assay 
Stokes Radius 
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StokesRadiiofSpectrinmonomer, dimer, tetramer, Spal-166 (Sl2C) and 
Stokes radius of spectrin dimer and tetramer were found to be 158 and 229 A, 
respectively, by Superose 6 column method. The Stokes radius for P-spectrin was 133 
A. The Stokes radius for Spa 1-166 (S12C) was 30 A. The Stokes radius for Spa 1-167 
was either 30 or 38 A, since two peaks appeared in the elution profile. Figure 14 includes 
the elution profiles for Spa 1-166 (S12C), Spa 1-167 and P-spectrin. Another peak 
appears in the P-spectrin elution profile and is probably a degradation peak. 
3.4.1.1.2 Stokes Radius of P-Spectrin and Spa 1-166 (Sl2C) Incubation Mixture 
Figure 14 includes the elution profile for the incubation mixture of P-spectrin 
with Spa 1-166 (S12C) (0.1 mg of P-spectrin was incubated with 0.012 mg of Spa 1-166 
(S 12C)). The calculated Stokes radii are summarized in table 5. A third peak was 
observed with a Stokes radius of 141 A. Residual Spa 1-166 (S12C) exhibited same 
Stokes radius (30 A). In addition, the area of the Spa 1-166 (S12C) peak decreased by 
16%. 
3.4.1.1.3 Stokes Radius of P-Spectrin and Spa 1-167 incubation mixture 
Figure 14 includes the elution profile for the incubation mixture of P-spectrin 
with Spa 1-167 (0.1 mg of P-spectrin and 0.012 mg of Spa 1-167). The calculated Stokes 
Figure 14: 
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Superose 6 gel filtration elution profiles of samples incubated in 
isotonic KCl buffer for 24 hours at 4 ° C. (a) P-spectrin. (b) Sp a 1-166 
(Sl2C). (c) mixture of P-spectrin with Spa. 1-166 (S12C). (d) Spa. 1 
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Table 5: Stokes radius of the incubation the Spcx 1-166 (S12C) and P-spectrin controls 
SAMPLE PEAK I STOKES RADIUS (A) 
Spcx 1-166 (S12C) 1 30 
P-Spectrin 2 133 
Spcx 1-166 (S12C) + P-Sp 1 30 
3 141 
81 
Table 6: Stokes radius of the incubation mixture of Spa 1-167 and P-spectrin and controls 
SAMPLE PEAK I STOKES RADIUS (A) I 
Spal-167 1 30 
2 38 
P-Spectrin 3 133 




radii are summarized in table 6. A third peak was observed with a Stokes radius of 141 
A. Residual Spa 1-167 exhibited same Stokes radius (30 and 38 A). In addition, the area 
of the two Spa 1-167 peaks decreased by 20%, respectively. 
3.4.1.2 Binding Constants 
The ratio of peak area in the incubation to that in the control sample was 
determined to be 0.80 and 0.84 for Spa 1-167 and Spa 1-166 (S12C), respectively. The 
equilibrium concentrations for the two mixtures were calculated (as described in section 
2.17.1) and summarized in table 7. Binding constants of 6.3 x 106 and 2.1 x 106 M-1 were 
calculated for the peptides Spa 1-167 and Spa 1-166 (S l 2C), respectively. 
3.4.2 Combined Western Blotting and Radiolabeling 
3.4.2.1 Affinity of P-Spectrin and a-Spectrin Peptides to Spectrin Antibodies 
Two monoclonal antibodies (SB-SPl and SB-SP2) and one polyclonal antibody 
were used in this study. The three antibodies were tested for their affinity to P-spectrin 
subunit and to the spectrin peptides Spa52-156, Spa 1-167, Spa 1-166 (S12C), Spa 1-446 
and Spa41-273. Figure 15 show three western blots for the three different antibodies. 
It could be observed that both SB-SPl and SB-SP2 monoclonal antibodies recognized P-
spectrin (to different degrees) and did not recognize any of the a-spectrin peptides. The 
polyclonal antibody recognized P-spectrin and very weakly the a-spectrin peptides. The 
monoclonal antibody SB-SPl was chosen since it shows stronger affinity to P-spectrin 
subunit than SB-SP2 and since the polyclonal antibody would give some background on 
the Western blots. Figure 16 shows SDS-PAGE of the same samples which shows the 
presence and position of P-spectrin subunit and the a-spectrin peptides so it can be 
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Table 7: Equilibrium concentrations for all three components in the incubation mixture 
ofSpal-166 (S12C) or Spal-167 with P-spectrin. 
SAMPLE I Equilibrium Concentration (M) 
Spal-166 (S12C) 9.7x 10-1 
P-Spectrin 9.0 x 10-8 
Spa 1-166 (Sl2C) + P-Spectrin 1.8 x 10-1 
Spa 1-167 9.2 x 10-1 
P-Spectrin 4.0 x 10-8 
Spa 1-167 + P-Spectrin 2.3 x 10-7 
Figure 15: 
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Western blots of spectrin peptides and P -spectrin using the monoclonal 
antibodies SB-SPI (a) and SB-SP2 (b) and the polyclonal antibody (c). 
Lanes 1, 2, 3, 4, 5 and 6 in (a), (b) and (c): the spectrin peptides 
Spa41-273, Spa 1-446, Spa 1-166 (S12C), Spa 1-167, Spa52-156 and 
P-spectrin monomer, respectively. Lane 7 in (b) and (c): spectrin 
actin. 
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SDS polyacrylamide electrophoresis gel (16%) stained with 0.05% 
Coomassie brilliant blue R. This gel was run for about 1 hour under 
a constant voltage of 160 V. Lanes 1, 2, 3, 4 and 5: glutathione 
affinity purified Spa41-273, Spa 1-446, Spa 1-166 (S 12C), Spa 1-167 
and Spa52-156, respectively. Lane 6: low molecular weight standards. 
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compared to the western blot. 
3 .4.2.2 Binding Between P-Spectrin and 1251 labeled Spa 1-167 
Figure 17 shows a Western blot of incubation mixture from two samples. The two 
rectangles containing dark bands (top rectangles) are detected by the antibody SB-SPl and 
thus contain P-spectrin. P-spectrin is present in these areas either as free P-spectrin or 
as a complex with radiolabeled Spa 1-167. These areas were excised and counted. The 
two bottom rectangles are the radiolabeled Spa 1-167 (free Spa 1-167) area and was also 
excised and counted. Counts per minute for the P-spectrin area (combined P-spectrin and 
complex) and for the Spa 1-167 area are summarized in table 8. The ratios of unbound 
Spa 1-167 to the total Spa 1-167 for the two samples were calculated for samples 1 and 
2 and found to be 0.37 and 0.42. The equilibrium concentrations of the three components 
were calculated (section 2.17.2) and summarized in table 9. Binding constant of 2.3 ± 0.3 
x 106 M-1 (n = 2) was calculated. 
3 .4 .3 Immunoprecipitation 
The binding constant was calculated as described in section 2.17.3. The ratio of 
bound Spa 1-167 to the total Spa 1-167 was calculated for both samples and found to be 
0.24 and 0.16 after subtracting the background (table 10). Equilibrium concentrations 
were calculated using these ratios and are summarized in table 11. Finally, binding 
constants were calculated from the equilibrium concentrations and found to be 5. 7 ± 4. 3 
x 106 M-1 (n = 2). 
Figure 17: 
89 
Western blot of incubation mixture of radiolabeled Spa 1-167 with 
P-spectrin from two samples. The top two rectangles show 
the stained P-spectrin and complex while the bottom rectangles 
show the area where radiolabeled Spa 1-167 usually appears. These 
four areas were excised and counted. 
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Table 8: Counts per minute obtained for ~-spectrin with complex bands and the 
Spa 1-167 bands excised from Western blot. 
SAMPLE BAND CPM 
1 ~-Spectrin 551 
Spal-167 326 
2 ~-Spectrin 229 
Spa 1-167 166 
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Table 9: Equilibrium concentrations of all three components of mixtures 
ofradiolabeled Spa 1-167 with P-spectrin. 
Number Sample Equilibrium Concentration (M) 
1 Spa 1-167 1.3 x 10-7 
P-spectrin 6.8 x to-1 
Spa 1-167 + P-spectrin 2.2 x 10-7 
2 Spa 1-167 1.5 x 10-7 
P-spectrin 7.0 x 10-7 
Spa 1-167 + P-spectrin 2.0 x 10-1 
92 
Table 10: Counts per minute for pellet and supernatant samples and calculated 
ratios of the pellet to the total counts per minute. 
SAMPLE Number CPM CPM RATIO 
(PELLET) (SUP.) Pellet/ 
93 
(pellet+ Sup.) 
Spa 1-167 1 2830 5413 0.34 
2 1676 4650 0.26 
Spa 1-167 + P-spectrin 1 581 5236 0.1 
2 921 8272 0.1 
Table 11 : Equilibrium concentration of all three components of the mixture 
of radiolabeled Spa 1-167 with P-spectrin 
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Number Sample Equilibrium Concentration (M) 
1 Spa 1-167 9.6 x 10·7 
P-spectrin 3.0 x 10"8 
Spa 1-167 + P-spectrin 3.0 x 10·1 
2 Spal-167 1.06 x 10"6 
P-spectrin 1.3 x 10·7 
Spa 1-167 + P-spectrin 2.0 x 10-7 
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3. 5 Spin Labeling 
3.5.1 Purity of spin labeled Spa41-167, Spa 1-166 (S12C) and Spa41-273 
Purified Spa41-167, Spa41-273 and Spa 1-166 (Sl2C) were spin labeled. SDS-
p AGE of these spin labeled peptides showed single band for each with estimated molecular 
weight of 15 kD, 26 kD and 20 kD which matches those of the calculated values. 
Densitometric analysis showed the percent area of the peptide band of all to be about 
100%. 
3.5.2 Molar Ratio of Spin Labeled Spa41-167, Spa41-273 and Spa 1-166 
(S12C) 
Spa41-167 contains one cysteine residue at position 167 which is the last residue 
in the spectrin peptide. Conditions such as spin labeling incubation time and the amount 
of spin label used were changed to obtain maximum spin labeling of this peptide. 
Maximum spin label to Spa41-167 molar ratio of 0.5-0.8 was obtained for this peptide. 
Spa4 l-273 contains two cysteine residues at positions 167 and 224. Spin label to 
Spa4 l-273 molar ratio was found to be 1.2, which is about double the value obtained for 
Spa41-167. Further, EPR spectrum shows two different populations of spin labels. This 
indicated that both cysteine residues were being spin labeled. 
Spa 1-166 (Sl2C) contains one cysteine residue that was introduced by site 
directed mutagenesis at position 12. Spin label to Spa 1-166 (S12C) molar ratio was 
determined to be 0.5 ± 0.03 (n = 3). 
3.5.3 Motional Comparison of Spa41-167, Spa41-273 and Spa 1-166 (S12C) 
EPR spectrum ofSpa41-273 show two populations of spin labels, one with slow 
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motion and the other with fast motion (Fig. 18a). EPR spectrum of both Spa41-167 and 
Spa 1-166 (Sl2C) show one population of fast motion (Figs. 18b and 18c). 
EPR spectrum of the Spa 1-166 (S12C) peptide was compared quantitatively to 
Spa41-167 and Spa41-273 by talcing the ratio of the peak to peak height of the high field 
peak to the peak to peak height of the middle peak. The lower the ratio, the slower the 
spin label motion. Table 12 summarizes the ratios obtained for the three peptides. 
Rotational correlation time was calculated for the three peptides Spa 1-166 
(Sl2C), Spa41-167 and Spa41-273 and found to be 1.8 x 10-10, 1.7 x 10-10 and 2.3 x io-10 
s, respectively. These values agree with the ratio of the peak-to-peak height of the high 
field to middle field and summarized in table 12. It could be seen from table 12 that the 
ratio of Spa 1-166 (S 12C) is higher than that of Spa41-273 and lower than that of Spa4 l-
167. The rotational correlation time of Spa 1-166 (S12C) is also higher than the rotational 
correlation time of Spa4 l-167 but less than that of Spa41-273. This indicates a faster 
motion for Spa 1-166 (S12C) than that of Spa41-273 and slower than Spa41-167. 
Figure 18: 
97 
EPR spectra obtained with 2 mW incident microwave power and a 
scan time of 60 seconds. a: EPR spectrum of Sp a 41-2 73. b: EPR 
spectrum ofSpal-166 (S12C). c: EPR spectrum ofSpa41-167. 
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Table 12: Ratio of the peak-to-peak height of the third to the middle peaks in the EPR 
spectrum 
PEPTIDE RATIO 






The First Human a:-Spectrin Structural Domain Begins with Serine 
(From J. Biol. Chem. (1994) 269, 25955-25958. See Appendix.) 
"The 106 amino acid sequence motifs of spectrin have been suggested to fold into 
stable structural domains, consisting mostly of coiled coils of triple helices. With the 
advent of molecular biology and biophysical techniques, structural studies of these spectrin 
106-amino acid structural domains became approachable. However, one of the difficulties 
in such an approach is determination of the correct phasing of the structural domains, 
which may or may not coincide with the phasing of the sequence motifs. Proper 
identification of the domain phasing is vital to the construction of stable spectrin domains 
for molecular studies. A previously published phasing shift for Drosophila a:-spectrin 
indicated a downstream phase-shift of 26 amino acids for the structural domains 
(Winograd et al., 1991 ). Using this phase-shift, we prepared recombinant spectrin peptide 
with the sequence from residue 49 to residue 155 of human erythrocyte a:-spectrin and 
found this peptide to be unstable relative to other peptides that we prepared. Using 
several other recombinant a:-spectrin peptides and following the protease digestion 
approach, we digested spectrin pepti~es with elastase and chymotrypsin and analyzed the 
102 
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amino acid sequence of the digestive products. We provide the first experimental evidence 
in identifying the first amino acid residue of the first spectrin domain in human erythrocyte 
a-spectrin as residue 52 (Ser)". 
4.2 Binding of a-Spectrin Peptides to 13-Spectrin Subunit 
Two spectrin peptides were used in this part of the study, Spa 1-167 and Sp a 1-166 
(S 12C). The segment containing amino acid residues 52-156 are folded into triple 
helical bundle. The N-terminal region (residues 1-51), though its structure is not clear, 
interacts with 13-spectrin directly. 
Three different methods were used to detect the binding between the 13-spectrin 
subunit and Spa 1-166 (S12C) or Spa 1-167 in 10 mM Tris, 20 mM NaCl, 130 mM KCl, 
1 mM 13ME, 30 µM PMSF, pH 7.4 at 4°C. These methods included the use of the gel 
filtration method (Superose 6 column on the FPLC system), combined Western blotting 
with radiolabeling, and immunoprecipitation. 
4.2.1 Gel Filtration 
The partial disappearance of the a-spectrin peak in the presence of 13-spectrin was 
used as an indication of a -peptide-13-spectrin complex formation. Furthermore, the peak 
areas of the a-peptide in the presence and absence of 13-spectrin were determined 
quantitatively to obtain equilibrium concentrations of the a-peptide and of the complex. 
The binding constants were found to be 2.1x106 M-1 for Spa 1-166 (Sl2C) and 6.3 x 106 
M-1 for Spa 1-167, both at 4 C. 
Gel filtration method was used to determine binding between the a I fragment 
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(residues 7-639, which contains 5 domains with a molecular weight of about 80 kD) and 
P-spectrin (Speicher et al., 1992). Binding constant was determined to be 4.5 x 106 M-1 
at 0°C. 
4.2.2 Combined Western Blotting With Radiolabeling 
In the combined Western blotting with radiolabeling method, the radiolabeled 
peptide concentrations in both free form and bound to P-spectrin were detected 
quantitatively. The average binding constant was determined to be 2.3 ± 0.3 x 106 M-1 (n 
= 2). This value is comparable to those obtained from gel filtration and to the published 
value mentioned above. 
4.2.3 Immunoprecipitation 
This method has been used qualitatively in binding studies of different peptides 
from a- and P-subunits of Drosophila spectrin (Viel and Branton, 1994). We have used 
this method quantitatively on purified cx-spectrin peptides and P-spectrin subunit. As with 
the combined Western blotting with radiolabeling method, the concentrations of the 
complex were measured quantitatively from a mixture of the P-spectrin and the complex 
in the pellet. The unbound peptide concentration was measured in the supernatant. 
Binding constants, at 4°C, were found to be 5.7 ± 4.3 x 106 M-1 (n = 2). 
4.2.4 Comparison of the Three Binding Methods 
Although these three methods provide similar binding constants, there are 
differences between these methods. 
The gel filtration method requires the measure of the difference in the ex-peptide 
concentrations, obtained from peak area, in samples with and without P-spectrin. These 
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two samples cannot be run simultaneously. Thus a great care is required in loading the 
control and mixture samples to ensure identical experimental conditions. 
In the combined Western blotting with radiolabeling, two components are being 
detected thus eliminating the need for using controls in calculating binding constants. 
However, this method is very laborious and requires a long time of processing samples 
including blotting overnight. Also, it involves excising the spectrin peptide bands, which 
are not stained and thus care is necessary in excising these areas of the Western blot. This 
problem could be solved, however, using additional polyclonal antibody which recognizes 
the a-spectrin peptides (although to a lesser extent) in addition to P-spectrin. 
In the immunoprecipitation method both the unbound peptide and the complex are 
being detected. However the presence of background binding of unbound peptide to the 
antibody presents a source of error. The control sample is needed for calculating binding 
constants. This method is the fastest of the three, and many samples can be processed at 
the same time. 
Although the three methods are different, the calculated binding constants, 
appear to be in good agreement with each other, ranged between 2-6 x 106 M-1 at 4 C. 
These values are also in close agreement with the published value of 4.5 x 106 M-1 for the 
al binding to the P-spectrin subunit. Thus the binding of these two peptides to P-spectrin 
resembles the binding of the al fragment to the P-spectrin. These peptides appear to be 
a good model system for studying association properties of a p spectrin. Other workers 
have found that P-spectrin-al equilibrium at the 37 C gave a binding constant of 1. 4 x 105 
M-1 (DeSilva et al., 1992). Binding was found to increase with decreasing temperature. 
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The binding constant was found to be about 1x106 M-1 at 30°C and further increased 
to 4.5 x 106 M-1 at 0°C. In addition, a cloned peptide with the first 158 N-terminal amino 
acid residues gave a binding constant of 6.6 x 105 M-1 at 30°C (Kotula et al., 1993). 
Since the a I domain does not contain the first 6 amino acid residues, it was 
determined that the removal of these residues did not affect the head-to-head interactions. 
The removal of the next 10 amino acid residues decreased the binding by 50% (Speicher 
et al., 1993). Cloned peptides that did not contain the first 27 amino acid residues did not 
show any binding to the P-spectrin (Kotula et al., 1993). Peptides including the N-
terminal amino acid residues of a-spectrin without the folding domain did not bind to P-
spectrin. It was suggested that the first folding domain acts as a template for the folding 
of the less ordered N-terminal residues and its presence is thus necessary for any binding 
study. 
Thus the use of the peptides used in this study as well as other modified peptides 
may provide insights toward binding sites of head-to-head association in spectrin. 
These peptides can be used as a model to represent the spectrin molecule. The head-to-
head interaction region could be studied in a more detailed way. Deseases associated 
with this area could be more understood with these models in hand. Our preliminary spin 
label EPR results on the a-peptides indicate that EPR will be useful in obtaining both 
binding and structural information on the N-terminal region of a-spectrin. 
Conclusion 
In summary, we have prepared spectrin peptides Spcx 1-166 (S12C) and Spcx 1-167 
107 
to high purity while preserving their stabilities under experimental conditions. The N-
terminal portion of these peptides (amino acid residues 1-51) are involved in binding with 
the P-spectrin. The central portion (amino acid residues 52-156) fold into triple helical 
bundles, while the remaining part (amino acid residues 157 - 166/167) is assumed to be 
loosely folded. We demonstrate their binding abilities with the P-spectrin with three 
independent methods. The binding constants were 2-6 x 106 M-1 in isotonic KCl buffer at 
4 ° C. Thus the two peptides can serve as a good model for a-spectrin, they include a 
folding unit and have similar binding affinity to the P-spectrin subunit. 
Now this system is poised for comprehensive studies to obtain structural 
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The 106-s..mino. acid •equence motiC. o( •pectrin have 
been •uggested to fold into •table ocructural domain" 
consisting mostly o( coiled coils o( criple belices.. With 
tbe advenc of molecular biology and biophy•ical tech· 
n.ique•. •tructu.ral studies of these sp.,ctrin 106-s..mino 
acid Hructur:il domains became approachable. How-
ever, oae o( the difficultie• in •ucb an approach is deter· 
mi.nation of tb.e correct pb.8'1ing o( the •<ructunll do-
mains. wb.ich may or may not coincide with the phasing 
o( the •equence motifs. Proper ideatificatioa o( the do-
main phasing is vital to the construction o( •table •pee· 
trin domai.a.! for molecular studies.. A prev;ou.oly pub-
W.bed phasing sb.ift for DM>1opiaila cr-SJ>""trin indicated 
a dowustt"eam pbase-•hift of !?6 amino acids for the 
.rructural domain (Winograd. E.. Ru.me. D~ and Bran· 
ton. D. (l99ll Proc. NatL Acad. Sci. U.S. A.. 88. 10788-
10791). Using this pbase-•bift. we prepared a recombi· 
na.nt spectrin peptide with tb.e •equence frum residue 49 
to r-e•idue 155 o( human erytbroc~e a-spectrin and 
found this peptide to be W1St.able reiative to other pep• 
tide5 that we prepared. U!ing several other recombinant 
a·•pectrin peptides and foUowing the protea.se digestion 
approach. we digeHed •pectrin pepcides with elast.a.se 
and chymotr;.-p•in and analyzed the ilmino acid •e· 
quence o( the digestive product.s.. We provide the first 
experimental evidence in identifyino; the first amino 
acid .-..sidue o( tbe first •peecrin domain in human 
erythrocyte a·•pectrin "-' residue 5Z (Serl. 
Underlyin; ~he ~ytoolasm1c surface of thf! human erythro--
cyte membr:Jne is .l dlll!nsP.. cwo·dim~nJ1111onal network of spectrin 
•~ts worK w~s sup?orted in part -,~ A.rnencan Heart . .\.ssoc:tauon 
Gnt.nt 91·10i6. ::ie 1'111t1on11l SC1enee F'ound.1t1on . .Jnd Loyoia Unrver.nty 
of Cruc:S.('l. The C05t.S of :iu'oltclt1on 11( this .:lr"t\Cl~ "'er'!' rl:~fr.J:-"ll!d in ;J3r": 
by the p11vment of pa~e Ch3f1e~. ThlS an.1c\e mu.H therefor~ be her'!O'." 
ma.riced ·~at.·trtut"m('nt· :n 3ccorci:ince ......,tn :3 U.S.C. St-Ctton t7J4 
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and other ;iroc.eins that ;irovide• support to the lipid bilayer 
and maintain• the ervt.hroc:yte nelClbility ! ll. Spectrin. which. 
<ompn•es a· and '3-•ubunii:.s. ;ilay• a cntical role 1n maintain· 
ing the architecture and therefore the inc.e~ty oi the red cell 
membn.ne. :-.,{a.ny ilered.itary hemolytic anemias t.nvolve 5pe<:· 
trin mutations i2-7'. In addition. sever3.l other proteins. 3uch 
35 dystroph1n. a-11ct1n1n. ribnn. '!t.c .• 1hare man~ properties 
nmilar to ti\ose of er,rthroc)"te spec~rin :ind are grouped a...s the 
•pe<:rrin suoerfomi\y ( ll. ThtU. it is import:int to undent.:lnd 
the structural proper-":1es oi spectnn. However. little !X;>eri· 
mental infonnatton is available to descnbe the detailed thne-
dimensional .CrJcrure oi spectrin. Amino ac:td (8) and cDNA!9, 
101 sequence anaJy5es of human eryth~ •pectrin (will be 
referred to as human •pec::rin bereafter: other types of •pectrin 
will b<! dearly •ta.tedl reveal that most part• of both •Ubun1t.s 
consist of homo\0~11us 'equence motifs. Each motif conslsu of 
abcJuc 106 arruno acids in len;th. Th!?re are :!2 5equence motifs 
i.n tandem in the a·~ubunit and 17 sequence motif3 U\ the 
13-subunit. Thue •equence motifs bave been sugge•c.ed to fold 
into stable structural domains. consisting mostly of coiled coib 
of :riple belices ( ll. 12l. With the advent of molecular biology 
and biophysical techniqu'?s. structural studies of .::hese !pectrin 
106-ammo acid struc:ural domains ispectnn domains! b«ame 
ipproachable. Recently, :he <-ray •trUcture of a homodimer af 
a 106-am.ino acid fragment in •egment l4 of Drosopnila. a-•pec· 
mn has been published (13l. However, one o( the diffic:ulties in 
such a.n approacb is to dee.ermine the cornet pbasing of the 
•trUc:t:un..I doma.uu. which may or may not coincide with tb.e 
pbasing of the sequence motifs. 
Winograd et aL ( 141 provided experimental evidence from 
DrosopAila a 0 spe<:trin fral;meni:.s :0 •ugge5t a down.5tream 
pba.se-shift of 26 amino acids for the •trucrun.l domaiD. such 
that :be first amino scid in a folded unit is residue 26 in the 
106-residue sequence morif .. "'5summg human a·•pec:trin bas 
the same pba.se-sb.ift as D.-o•o.onila a-spectnn. th.e fir>t amino 
acid at the N·termmal end of the first nnictur:il domain !Ml) 
·.vould be rosidue 49 'Leu l. since residue H I Ile' i• the first 
amino acid oi the first •equence motif in human o-;peetrin I 9). 
3ased an infonnation obtained from proc.ease protection anal· 
ysis ( l2l. Speicher ec aL ( 151 •uggest thac structural domairus 
beg;n and •nd around residue 30 of the sequence motif of 
o-spectrin. Th••• phase-•hilt.s have be"n used :.o conscruct 
stnictur.11 models or recombinant peptides. The Winograd 
pha•e-shift ( 141 was u•ed to construct recombinant pepcides 
either of a·•pectnn for x·ray studies 1 l3l or folding •tudies I 16) 
or oi 13-spectrin for >upra-motif studies ( 171. The ph:ise-shitt af 
dy!trophin ·.vas compared Mth Winogr:id"s phase·•hift in •pee· 
:nn and was found :o be different by an upstream •hilt of 9 
omino ocid• I 181. The Speicher ph:i••·•hift ( 121 w•s used to 
constr.ic~ recombin.'.Jnt peptide! for spiec:nn utr:J.n'ler bindin5f 
site studie• I 15 l. Kennedy et al. ( 191 st:ited th:it the phasintt of 
~he .cnictur::il dom:nn m 13-specmn is shilled appro:<im>tely 
~O-.JO res1due5 tow:ir-i :he C temunus compared 'N'lth the phas· 
ing of the 3equence mot:fs. 
:-lot only do differ~nt publi•hed re•ults •ugg~•t different 
amino acids a.s A.Al for the •tr~c:ur:i.I domain. different num· 
benng •y!Cems for the amino acids in the •peetrin sequence are 
al•o tiled. 3efore :he ;iublic:ition of "'"'pectnn cDNA re•ults, 
Glu was residue l ~ccording :.o Speicher and :.ia~hesi !201. The 
human spectnn cDNA results detected 6 add.inonal amino 
acid.. loc:ited u pstre:im of G\u to give MEQFPKE 3..5 the iinc 1 
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Fie. l. Amino •cid sequence of human erythrocyte ~pec:tria from r"'Hidue 1 to 187. The cDNA numtMrin1 sywt.m ia shown and w.ed 
throu~out Uus presenut1on. £Ian.a-'• 1 ~ l and chymotTYl>stn (•l N!'COfNtion tic.es an included. Uttdttrilntti ar1"01L•s1a.sun$Ju indicac. sir..s of 
enryme cleavage u reporc.ed her-e. The amtno aad residues ;n the tlnt a·spKt.nn nT'Uct\lraJ dom&lll are sit.arUd. 
amino acids in a·•pearin 19). Thus ~sidue l (Glu) in the pre-
v;ou.s aumbering system (20> is now residue 1 in the cDNA 
aumberillg system (91. Both aumb.,ring systems are u..ed in the 
literature. altbou¢ not ne<:essarily clearly referenced. for all 
types of spect:rin. Parry and co-workers <2ll identify the start-
ing position of the tint scru=al motif as residue -46, uaing ti!" 
aumberillg sysu.m of Sp<!icher and Mar<:hesi (20). Yan and co-
workers ( 13) in tll"ir work on segment 14 of Dro•oplr.ila a•spec-
trin use the c:DNA numbering "Y•tem. w., follow th" cDNA 
aumberillg syn.om in this ~port tFii;. ll. 
Using '"veral r...:ambinant human a-sl>"Cttin P"Ptides and 
foUowuig the protease dig~scion 3pproach used by >1rrnograd 
and co-,.orkers f 14 l. we provide the first experim.,ntal ev;d.,nce 
in identifying the first 3m1no acid rosidue of the first spe<:trin 
domain in a·sp.,ccnn. Prop<!r identific3tion of domain phasing 
is vital to the construction of stab!" spectrin domains for mo-
lecular studies. Our r..sult.s show that the first spectnn struc· 
tural domain suru W1th residue 52 !Seri tFig. ll. 
!11.ATERW.S AND METHODS 
Sp«tn.fl Rtt0mb11ta1tc Ptptld1.1-The cDNA done aJ that contain. 
the N•t.enninal ~g1on a( the a*Jubunit 191, a !feneorou.s ('ift. of Dr. S. G. 
Fo~t (Yale Un1ver."1C.:O' School of M~icine. :-.Sew Haven. CT1. wa1 lin· 
Hnted ..,,t.h, Sacil 1.nd us~ ... a template. Oliconucleoude pnmer 
contaJruo-c nquence r:vrT'5pondinJ to residue• t-9 of a·~Qeetnn. in a 
'crue onent.u1on. a.nd pnmer cone.amine ,equenee eort'esponding to 
re9iduu 159-167, 1.n an anllaenJI! onentauon. wen tynthfttzed by 
N•aoo.aJ Bio9C1ences , Plymouth, ~tNl and used to make the spectnn 
eoneQ"'Uct. o( a ~i>t1de W'lth the t,pquence of <J·tpectnn from t"e'1due 1 to 
re11due tST <Spal-l6it 1 The published a•tp.ectnn Hquence 19) wu 
UHd. Similarly • .!pitoetnn c:onnrucu ofSpa49-lS5 01nd Soo'49-167 were 
Li.so ?rep~. Some o{ the oliconucleoude pnmen were 1ynthcs11ed by 
the Weib Cent.er Oli11onuc:leoude Synthesu:er Labontory. The JJ>ec't?'ln 
C1)nltruc:u were lipted into tbe BamHI .1.nd EcoRI StteJ of the (Jut.a• 
~one S ·traruiense 1 GSTJ eXl)resa1on \"Ktor ?C C:X·ZT f Pharmaaa Bio-
ted:l tnc.l. These liJ&tions ••~ 1n.fr.sme wtth the GST protein. The 
1 The abbr-eviattoru: use<i are: Spal-1Si. a. ~ot1de Wlth rhe uquenee 
of a·'I~ from ru1due l to ~"du• 157 r11rnd:1r :ibh~Y1at1on system 
WU u.se<I for other l)e?t•du1: OST. rlutathione S-cr.insfen.n: F"?LC. 
fut prot.ern llqu1d. ehrom•t.0(nol"ly: M 1. the fir3t am1,,o acid It the 
N-t.enrunaJ end oft.he fi.nt. structural domain. 
pGE:X-ZT vector eonta.1ns a. t.hrombin c:leava,e sic. betwffn GST and 
the i.Q.Hn.ed geRe. i.1. s~n con1uuct. The speccna pepcidH wen 
locstod in11J1edia!.t!ly foUoW1nf the thrombU. cleaYOC• si ... Tho expru-
tion o( (wion protein wu under the c:oncrol of a /Jx pnnnoc.ar. Thu.a. 
hitlh. inducible l•••ls of fuaion pro .. iiu we.-. produced. 
The ovft"1Jrociuced f'uslon tJT'OUtn 1GST·thrombin cleavage site--spec· 
tria pepC'idot ..... l"'KOvered from: b•ct•ri.a.J lrsate and pUHd <JY..- a 
1iutachion• •tnni~ column tf' ••• rlur.athioa...seph•rvM 48 from Pbar. 
maaa), uainc published method.s f 221. The column. with the bound 
N.s1on protein. wu e.nen..11vely waahed.. followed by elution .,th buffer 
conta.u:Unr fresh rlut.at.h1one. The spectria ~pcida .... cleaved from tbe 
GST by immobili:i:ed tl\n>mb1n rel rCaJbiochem1 and eluted ...;th GST 
a.ttd residual u.ncleaved fusion protein from the gel. The mixture wu 
pused over the g!utatttione affinity colwnn again ta remove GST and 
residual fu!lion protein to i'lv• relari¥ely pure spec'Cnn peptides. lC nee· 
us.a.ry. the pe9ride:1 were further purified b~ faat proteia liquid chro-
ma tnVilnhy l F"PLC1 W'\th a ~ono Q column 1 Phannac:iaJ. u.sinc 40 mN 
Tris at pH i.5 and an NaCl indient. 
E"-;t''"~ Di1ut1on and Prpridt St"qurncui..f-E:last.ue (nJm porcine 
pan~as ISi(Tn&J in 5 mM Tris st pH S.O ..-as mixed .,,th 1 spirectrin 
i>"Ptlde at a w•t~h< ruio o( l:l2.5. in 50 m." Tris at pH 8.8 and room 
temperature. Samplu were ta.ken from the mixture at various time 
pcnnu for gel electr0phore,1a analysis. Sin:ularly. ch~-mocryp11.a Cram 
bovtne ?•ncreas <Sirma• tn 1 m.'4 HC1 was mixed .;th specinn peptide 
at a Wf'•Jht ratio of 1:400' 14l. in 40 n:l'.\f Tri1 wtth 12.5 m"8 NaCl ac pH 
i.S and room tempentutt. l?tr po•~•c-r:-·lam1de set elKtropho~tia ••• 
perfomu!•d us1nc ~l~troph.01""1!915 buffer cont:unin~ o . .sc:;. sos. L.ow ra.nre 
pra~tn molecular mua n.;indards I Life Tffh.nolof1es. Inc.J at 43.0. :29.0. 
18.4. 14.3. S.2. and J.O kD• wore uaed to cu•d• th• mol~ar atLSS 
ca.Jcu.lac.ion.. For amino aad :sequence analysis. polrvinyiiden• dilluondt 
membnnes tApl)lied Sio,yst..ems. Foster City, CA» were uffd for elec· 
troblotttnc. The 11m1no acid tequencinc of the d.icetuve product. was 
done by the Uruven1ty of [!linots BioW'chnoloa C~nter. 
RESL"1..TS A.'ID OISCt.'SS!ON 
Using Winograd's down•cream phas.,.•hift of'.?5 3mino acids. 
we designed Spa4~ 155. a P"Ptid" w;th lOi amino acid resi-
du"s and with Ml at position 49. to be a P"Ptid" that included 
the first stab!" structural domain of human a·sp.,ctrin. How-
ever, Spao19- l55 was found to be unstable wh"n compared to 
the other Spa peptides that ,.;n b" discuss"d b.,low. The elec· 
trophor.,cic gel of Spa4~ 155 purified by FPLC techniqu"s e:<· 
hibited several bands. "'1th th• predominmting band at 12. i 
kDa and two minor bands at about 9.8 and 8. 7 kDa cFig. 2A, 
1 l l 
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:'le. :!. SOS-PAGE: (18"- Jell o( .,._......, d.iceniaa produeu o( 
~tri.a peptide-a.. ata.i.aed trtth Cooau.,,,.te arilllanc Blue.. A.: 
ltvw f. F'Pt.C-puri.fied Spa"9-t55 !no '!i.uu.e preMnc.1: ta~:!. 10 ~ 
.ul.er ':.be tncroduec.oa of eia.su.M. at a pepad• to enzyme •eurrit r-auo of 
t:!..S:l.; lan.t J. ~O imn: laiv 5. JO r::Un: La.iv 5. -40 cnJll: ian~ i. 50 cue.: lanf' 
'· 50 tmn.. ~ 4. cnoll!'C'Ul.ar :nus .s~danfa. 3: la~ l. :?!..C·c~fied 
Spa-49-167' (no eia.Jtue p~senci: ialf.f' 2. l :-t: !a.n~ J. :! ~: !artf' S. j h: lanf' 
;, '4 !'\: .1..nd lanf' 7. 5 h. lan~ 4, ci;olK".Jlar 0'\8.55 itandardJ, 
lartt I l. The mo!eC'~lar :nass for Spa49-l55 caic-.:iat•d irom <he 
5.equenc:e was lZ. i k.Da. Thus. -=v@ b4!lie .. ·e th~t ~h'" o;iajor band 
•a.s to.hat of Spa49-t55 a.nd t~f! :iinor !l:ind.oe '''~!"'~ rror:-:. d~';"!"':l.· 
dac1on prcduct.S of Spa49-l55. In :.he presenc!! of >?!asuse. at .i 
wet~ht rar:o of l:!.:?.5 . .5pa49-L55 wa..s quickly dif{ened int0 
smaller f:-:l~enu .. ..\.t t • to min. bands beio\\" t:.: ~D., ap· 
~ared l: low 1nti?nS1tles ·..,,::.h :::mc"...lrrent decrease tr\ the '.n· 
i:..enstty of the t'.!. 7 -Wa ~3:id (fan.~ 1 ! . • ..\.5 i:.he dj~est.Jon ~ac:~on 
'-Y'lth 1?ia.st.a.se proce~cieci tu~her. a. sc.e11dy decrease in -:.he in· 
~nst:Y oi the t::?. 7-kDa band .1.nd an 1nc:-'!a.5e in. :::e :ntensltie~ 
of !he 1maller bandl were abser.~-!d 1 ian~s .1 md 5-7). At t ll 50 
m1n. ~he hand at tZ.7 '.<Da w:is no lonq~,. 1-!tec<:.:ible but flint 
bands below l'.!. 7 k.Da W'!r~ ...,siO~e { {artr 31. in cont.r3.St. under 
!imi!ar cond.it.1ons. :he ~eoc.Ide 5pa49-L57 . ..,u quite 3tabl-e. 
Spa49-l67. '-Nit.h J molecular :-nass of l-4.:1 :.c..Da :::iiculated from 
"...'i.e ,equence. aopear~d ~ a SU'l~ie band .lt. LJ.2 Wa on the sef 
! ::i;. ~. !c:n~ ! l. :\..Jler :J: 50·min di~~st1on .... ,,:n ~i:isuse under 
:..""le condi:.10n5 iisted Jbovl? for Soa,.9-t55. :he Soa-t9-l6i di· 
sest:on produc: 3.00~ar'!'d J.S .l s1ngie band at ~3.'.? 1<..Da iian~ :J). 
~u ·:Jand ~rststed at : ':I '1 h 1 lan.~ J l. The intens1cy of ~his 
::isnd dee:-e!\~eid Jt: • J h (lane 5L a.cpenreci as oniy J fame :,and 
H: ~ --4 h ! lan~ .; ). :ind linaiiy ~C;J.me :iot detee~ble JC.! .. 5 !"\ 
(!aru 7). 1:'lu3 ~hese :iig~st1on ~suits SUOI6!5t Spa49-l57 ts 
folded :nto .t :-nore st.1.bie :::on:lg".Jn.t1on :h.:in Spa49-t55 J.nd 
:l::e raided Jtruc::u.r'! :-e:usts ~ias::J.Se digest1c::. T:,e ammo acid 
~s1ciues ~eyonci t55 tn 5pa49-l57 ~rnV"lde ~i~ments :a tOid :he 
p-eo~de into s more suole s::-.Jc::.;r~. 
7:1e :?~C-puniied ~eotide Sea l-157. 'Vlth :i ~oi~lar 
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F°!C. 3. SOS-PACE 118".4: gel> al ?M>U:olync .::lice~tioa o( Spal-
l67. naioe-d. wi.th Coom•Hie Srtlli•nl Slu-e. A. ei•.St.U<!! d.i11"t1on a( 
Spa:1-l6i. l.Al't< l. molec:u.lar ma.as st.at\d&rds: !a.rt< :?. Spat-t67 Ina 
~lut.a.5e present;. La~ J. ' n 1.fi..er ~..h. 1ntrodui:-;:ion a( elut.aae. at .. 
~~ud• ·.o eru:yme ...,f!Hfht r.1uo of t:?.S: l. Sands at 16.0 .ind. t'.!..3 'illa 
-~~ wed for !min.a •C"ld sequence a.nalyns. 3. =h.vmotr'Y1:Js1n difestion 
o( Soal-l67. Lanr l, :nolKUiar ma.ss standards: larut !. Spal-167 fn.o 
:.'iymotrr.u1n1: /a,,~ J. 90 min alter the :ntroduct1on o{ chymoc:nuin at 
a. ~ptide ~ en:~e ""'•t!Jht r-aao or ..tOO:l. Band a.c. 14.5 was used :or 
!'-t-tenrun.al ua1no acid sequence a.nalysis. 
sinil• band at about 21.0 illa rFii . .'.IA, iaru '.!l. Zlas=e di· 
;esrion of Spcd-tni <at we1-ght !"atlo o( l:!.2.5l r~sulted in ewo 
Oa.nds at 16.Q and 12.3 k.Da at l • 90 min. These cwo bands 
;:ier31st.ed 1n the digesuon mixture ac. t • 4 h t Fii. J.A.. lane J J 
The b~nd intensity be-c:J.me undete~...able J.t t • 5 h ! not shown i. 
Thes~ data SUiieSted that :he diiestton ?r'Oducts 'NI!~ very 
st.able peptides "'ken compa~ ""th Spa49- L55 and had siln· 
ilar subility u:i che dil!'estion p1'lduct ofSpa49-l6i, witic:h also 
wtthstood elas<ase dil!'estion be~oad ~ b. 
The N-U!nrunaJ sequence <Ula.lysi.s of the 12 . .3-lcDa fr-agmeat 
"'"" found co be EDSYHLQVFK. .,.itich aliirne<i perfectly .,,th 
50-59 i.n the a-spectnn sequence !Fil!'. ll. The ela..sta.se cle.avaie 
rites around :.b.is region of a-1pect..-in coostst of residues 46 
(Cly), 49 (t...uJ. and 52 (Serl, and cleavage ""'' at che C.ter· 
minaJ end of :he pepode eon!lst ~f n!>idues tS l CGly), t54 
(Leul.155CLeu1. !ST!AJa1. t5.~CLeuJ.and l64<'-iall. Wesu~~e•t 
that elastas'! deav~d at 49 <LeuJ and ac. 157 'Alai to give the 
?•Pride 5pa50-t57. which h:u a ca.Jcubted moleC'.ilar ::ias• of 
L.2 . .3 kDa. r:,e first amino aCld at !he N ter.n1nus of :his di~es­
eion :Jrociuet was dear!~ 50 1Gtu1. :is indiC3ted ~y i:he sequence 
3naJysu d.:ic.a. However. the last amino actd at :he C-c.er.ninal 
!nd ,,,as less eer'...atn and was su~gested by :nac..:hing gel ~lee· 
trophore51s m.olee....iiar r.iasses with cak·.:iac.ed molec" .. dar 
:':"13SSe~. (t "NBS .JiSO p0!11S1bie that the digesCIOn pnxiuC: "Ml!..5 
.3oa50-l54. Spa50-l55. or Spa50-l53. with c.:tlcuiat.ed :nolec· 
ular masses o( ~2.5. LZ.6. ar t2.9 l<...Da. respe-c':ively. 7hu.s :he 
::.i-i:.erm.1nal 'equence .Jnalys1s of the ~iasc.ase d...i.~!!st.lon pMduc:t 
l l::?.3 l<.Dal of Spat-l67 sugge>ts that AAl is •1ther 50. j[. or 
52. rr ..-\Al is 50 or 51. :hen :he first stable str.ic~ural domain of 
human a·,oeco:nn is Spa50-l54 or Spa5 t-i.55. since ~he first 
mot1f of a·!Oec:i'ln compn.ses LOS amino ac!d :'"~s1dues 1 201. ·.vieh 
.J moiecular :nass of !:2.5 or 1:2.S i<.03. resoee~:v~I~·. How~ver. '.Iii'~ 
found that :h~ elascase digestion product o( Soa49-LS3. a pep-
tide ~hat •ncomoasses both 50-l54 •nd 5 i-l55. did not ;ired· 
uce J.n;" i'eotldes 'N"lth >t."10tiity :Hmdar to :hose found in :he 
di~est1on :>roducts of the other peptides ~h.Jc. "Ml? studied. -::-iis 
piece of !V1dence sug~~sted th:it the C-ter.n1nal ~sidue of the 
iint .str.Jc:urai dom31n was beyond t55. '•\"'! -:one!ude :hat :he 
C-t.ennlna.l residue 13 lSO and . l..A.l ls 52. ~-~Ytn~ ;i stable struc· 
':.Ural dome.m of Spa52-l50. s~ed on this conclusion. 'Ne 5Ug· 
~est that Spai-L5i contains .1 fully folded s::-..lc:ur.J..1 domain 
wruch ts able ~ =-~'!'.St ~1:1Sta3e dil§'eStton. SL1sc.:ise will only 
:ii~~st Spa 1-167 ;it sites pnor !O 5:! .ind .Jt1.e~ ~56 to t1''1? :he 
d!g~st1on ;lroduc: 3pa50-t57. 'N"1th 3 molecular :nass of t.:?.3 
'<..Dl!L. A ..s discussed .i"oove. ~he diogestton ::iroduc! of Spa l-16i 
a.pp~s~d J..S .i i:>l!Lnd at l'.!..S :.tDa f f"'i;. J.A.. iane J ). 
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25958 Spec:r:n. Struc:uraL Domain. Be.gin.s with Serin.e 
The N-t.ermmal •0<1uence oi t.he l6.0-k.Da i'nipnent '""" 
found "' 0.. E:TA£E:IQERR •. ,.,ruch >ii,.ned perfectly ·N1t.h "'"" 
due:s 19-23 in the cz·i'Pe'C";T1n 3equence. The ~la.st.a.3e deava~e 
!ltt.es around t.hu re~on af (J-'!~r"!n con~ust ()f 17 (Val). t3 
(l,..eul . .tnd ~1 IA.la/. The poss1ble ;JeOtlde'5 w~re 5pal9-l54, 
Spal9-l55. Spal9-l57. or Spal9-l58. with caiculated molec-
·.i.lar :n~s~3 of 16.J. ~6...+. 16.5. or tl). T <.Da. ~5p-ec:wely. 'N~ 
1u~!:esc. ~h3.t :he ;>ept1de 1s ~tther .3pal9-t57 or Soal9-:5d. 
Th.U ?eonde ;JroCably ::Jnt.a1n.s Spa l9-.5 t. the so-.::i.iled ·~efi.x 
J .. I~'.:!!. which ts J.lso c::i.lied -~e!ix A· r l l l. ;>!us ~'ie :l.rst it.ab!~ 
:itruc:un..l domo.irl 3oa5:!-l56 Jnd re~1ciue lS-;'. 
·n~ also ~~rt"or.netl cn:'""lotr"Y?s1n :ii~~s::1on U> oht...lJ.n incie-
penden:: di~l!SClon prociuc:.s from 5pal-l57 C~ymoc:·-:r?srn h1u 
deava~~ :Htes diffe~nt ~·rom o:hose- or" elasuse. Alter '30 m.ln rJi 
chymotf"Y?s1n d.li;est.100 \a: a. wetii;:-tt :-:i-c10 i)i L:400!. :.."i.e :;m~!e 
hand oi" 5pal-~67 J.t :!LU k.Da :Fi~. JB. ~a:1~ 2) ;'!,ulted tn A 
ba.od.3 :it or Oeiow '.?L•J k.Ds.. W"'\th :!-le 3mailesc one J.~ .1.0out l-.l..5 
k.Da Ua1u J). Lne ~op band .it :!!.O '.<.Da wu ;issu.med to ':>e 
und.ige!!ted 5pal-l67, while !he other fivf! wer? chymotr:r,::i51n 
d.is;est10n ?roducu o( Spat- t67. :he :--f-ter.:iina! sequence inal-
ysi:t of the sm3ilesc hand u l~.5 '.<..Da r!v~1ied in :imino ac.d 
.. quenc• of KERVAE, :"'ruch :iJi,.ned perfectly "'1th posrnons 39 
<Lys> chrou~h 44 iGlul of :J.·1pe<~-.n. l.'le ch.ymotr:-rp:un deav-
sg• """ around.:hts r~~on consl!ted otJ5 (T\TJ, JS I ?heJ, and 
SJ fTyr1. J..'1d ~he deav1u;e 51te:t .it :he C·ternunal end of this 
oeoe1de consisted of HO iTrni. tBO 1?he1. >nd l53 <Tyn 'l."e 
~u~ested chat :~e chymac-r:.,;stn di;~sc10n produc-:. at l~.5 Wa 
wu 5pa39-t50. wh..lch. ha:t a :::Uc·.:.lated :nolecuiar ::n.a.ss of 14.5 
Wa. rt is .J.iso possible ~.hat :.he d.igest1aa .'Jrociuc: -:vas Spa39-
L6J. "Ith a caiC".tlauod :nol«Ular :na.5• oi 14.9 k.Da. The cny· 
~oc:-ypsin d.i~e:taoa dac.a. tnd.iC3.te :.b.at • .\.Al i.:s betwe-ea r"'!'5'due! 
J9 s.nd SJ . ...,ruch suopor"..1 the concluston obta.tned f::-om :he •la.s-
:rute d.i'fe,tion dat.:J. to i.ndic.ate t.1&.t A..A. l :s 52. Thu.:s our exoer· 
imeota.l results lnd.iC!lte ~at :be IDc a.auno acd in ~lie hu.::Da.n 
a-!pectr.:i. stt'Uc:u.rii domain !.5 5:? (Ser1. wh.ich co~spond.s ~ 
a dowtlsq-,,am pha.se-•hift oi ~9 uruno acd '°"sidues frum '.be 
sequence mocif reporud by Spetc!:ier and ~!ar:.'iesi l~Ol. 
It u tnur~Sct.ni o;.o note ~ac "Nhen w" -:ar~iully studied the 
!equences publi:thed i...'1 :he Hter:iture on work ~hsc ~C?porteci..ly 
·..l9ed :!ie \\iino~!J.d ;frtase·ihift ( 13. 16. 17) i:.o pr~oar~ :-ecomC11· 
:ian: !'epctcie.!. w~ fou.nd :.hac ~tacDoniid -!t al. r 16) had used. a 
?il.:ue-shift corresoondi.n'{ :o res1due -+9 f~u1 as . ..\.A.l. ·Nhereis 
3y'!M et ~l. ( l j') :ind "(an ec aL. 1 lJ) had u.sed 3 i-)h3.Se-'3h1f't 
:or.--,_!Joondin~ oo .5~ !Se:-1. 'N'! :i:id =1en~oned >!sriie:- ~hat in 1 
=iodeiir:~ study. ?i,-:-:1 o?t al. I:!!) tci~nr-:f:: :.he 5t.a.r:1ng ?0!1t:on of 
~e ti.r'5t 3tr"'..:.c-:.'..l.o3.l ~otif J.! :--e,1ciue 46. ·..vit.i :hex: nurnber.!'t; 
sy•tem •ccurtlim: '° Speicher ind ~!s.rcileoi ('.:Ol. Since :his 
"umt><.nn~ •Y•tem star-3 ""1t.'1 unmo acid 7 <Glu) a.a t, :.'ti• 
:no<ieiic'!' study h"-' also piaced AAl J..S 52. Th=. Ml bet.n'!' 52 
:ru~nt have ~n :!Ul!!'gest.ed ~a.rHer without. e.xpenment.al '!vi· 
d.ence ia. the liten~ure. rtow~ver. :!tnce ':he pha5e-shift.s wet""! 
:iot dearly Stated .l.!J 52 rSer> in 3ome of the3e 5tudies Cl.3. 17), 
:11fferenc. ;Jh~e-•hif"'...s have ':>een ~ed -:a pre:p~ ~ombinant 
;pec::r:n ;>epttde• 1 L6. t3. l9). 
Our ~X;>4!nmen::.::U :>tudies 1how thac. J.mino 5cid.:s 52-155 in 
~uma.n :J.•5pec::""'!'n J.r~ fold~d 3..5 a st..:ible n~c:-:.'.J..rai dom3Jn. 
?;~parnc:on of :h13 and r'!'\ated pepc1cie' ior btophysical nud.ies 
·,,.,,,ll ;Jrovide •.u . ....,t.h cieta.ded st:-'.J.Ctur:i.i 1n..for.n;it1on on -'P~rin. 
Adtnowi~dftn.en.u-We tk.:iru<. <:lie l.\.·~us Ceot.er- Oli(Onudl!'Oude Syn-
thnner L..lbor•t.Of""Y for wnthes1:.1nt( JOme .,( ~~e oli~nucieocdu ·aed 
:n ~.h.u ·•one:. '.Ve than.<. Cr. 3. (;. :or'i;~t of"{a..ie l:n.iven1cy for ;:iroV1din( 
'.!a .._,,th sp«-:.nn :ON A done5. 
•. 3t>nn•<t. V. •nd Ci:tirsn. D. ~- l L9"ll Ari""- ittv. C-<il 3U>l. '· :!1-?6 
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